


# The enteric nervous system relays psychological stress to intestinal inflammation

## Graphical abstract



## Authors

Kai Markus Schneider, Niklas Blank, Yelina Alvarez, ..., Robert O. Heuckeroth, Maayan Levy, Christoph A. Thaiss

## Correspondence

maayanle@penmedicine.upenn.edu (M.L.),  
thaiss@penmedicine.upenn.edu (C.A.T.)

## In brief

Psychological stress and chronically elevated glucocorticoid levels induce inflammatory enteric glia and transcriptional immaturity in enteric neurons, leading to dysmotility and predisposing the intestine to monocyte-mediated inflammation.

## Highlights

- Psychological stress leads to monocyte-mediated exacerbation of gut inflammation
- Chronic glucocorticoid signaling drives the effect of stress on IBD
- Stress induces inflammatory enteric glia that promote monocyte recruitment via CSF1
- Stress provokes transcriptional immaturity in enteric neurons and dysmotility

Article

# The enteric nervous system relays psychological stress to intestinal inflammation

Kai Markus Schneider,<sup>1,20</sup> Niklas Blank,<sup>1,2,20</sup> Yelina Alvarez,<sup>1,20</sup> Katharina Thum,<sup>1</sup> Patrick Lundgren,<sup>1</sup> Lev Litichevskiy,<sup>1</sup> Madeleine Sleeman,<sup>1</sup> Klaas Bahnsen,<sup>1</sup> Jihee Kim,<sup>1</sup> Simon Kardo,<sup>1</sup> Shaan Patel,<sup>1</sup> Lenka Dohnalová,<sup>1</sup> Giulia T. Uhr,<sup>1</sup> H  le C. Descamps,<sup>1</sup> Susanna Kircher,<sup>1</sup> Alana M. McSween,<sup>1</sup> Ashkan Rezazadeh Ardabili,<sup>3,4</sup> Kelsey M. Nemece,<sup>5,6</sup> Monica T. Jimenez,<sup>7,8</sup> Lila G. Glotfelty,<sup>1</sup> Joshua D. Eisenberg,<sup>9</sup> Emma E. Furth,<sup>7</sup> Jorge Henao-Mejia,<sup>7,8,10</sup> F. Chris Bennett,<sup>5,11</sup> Marie J. Pierik,<sup>3,4</sup> Mari  lle Romberg-Camps,<sup>12</sup> Zlatan Mujagic,<sup>3,4</sup> Marco Prinz,<sup>13,14,15</sup> Carolin V. Schneider,<sup>16</sup> E. John Wherry,<sup>8,17,18</sup> Meenakshi Bewtra,<sup>19</sup> Robert O. Heuckeroth,<sup>9</sup> Maayan Levy,<sup>1,8,\*</sup> and Christoph A. Thaiss<sup>1,8,21,\*</sup>

<sup>1</sup>Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

<sup>2</sup>Faculty of Biology, University of Freiburg, 79104 Freiburg, Germany

<sup>3</sup>Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, the Netherlands

<sup>4</sup>School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, the Netherlands

<sup>5</sup>Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

<sup>6</sup>Department of Neuroscience, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

<sup>7</sup>Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

<sup>8</sup>Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

<sup>9</sup>Department of Pediatrics, Children's Hospital of Philadelphia Research Institute, and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

<sup>10</sup>Division of Protective Immunity, Department of Pathology and Laboratory Medicine, Children's Hospital of Pennsylvania, University of Pennsylvania, Philadelphia, PA 19104, USA

<sup>11</sup>Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA

<sup>12</sup>Department of Gastroenterology, Geriatrics, Internal and Intensive Care Medicine (Co-MIK), Zuyderland Medical Centre, Sittard-Geleen, the Netherlands

<sup>13</sup>Institute of Neuropathology, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany

<sup>14</sup>Signalling Research Centres BIOS and CIBSS, University of Freiburg, 79104 Freiburg, Germany

<sup>15</sup>Center for Basics in NeuroModulation, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany

<sup>16</sup>Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

<sup>17</sup>Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA 19104, USA

<sup>18</sup>Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

<sup>19</sup>Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

<sup>20</sup>These authors contributed equally

<sup>21</sup>Lead contact

\*Correspondence: [maayanle@pennmedicine.upenn.edu](mailto:maayanle@pennmedicine.upenn.edu) (M.L.), [thaiss@pennmedicine.upenn.edu](mailto:thaiss@pennmedicine.upenn.edu) (C.A.T.)

<https://doi.org/10.1016/j.cell.2023.05.001>

## SUMMARY

Mental health profoundly impacts inflammatory responses in the body. This is particularly apparent in inflammatory bowel disease (IBD), in which psychological stress is associated with exacerbated disease flares. Here, we discover a critical role for the enteric nervous system (ENS) in mediating the aggravating effect of chronic stress on intestinal inflammation. We find that chronically elevated levels of glucocorticoids drive the generation of an inflammatory subset of enteric glia that promotes monocyte- and TNF-mediated inflammation via CSF1. Additionally, glucocorticoids cause transcriptional immaturity in enteric neurons, acetylcholine deficiency, and dysmotility via TGF- $\beta$ 2. We verify the connection between the psychological state, intestinal inflammation, and dysmotility in three cohorts of IBD patients. Together, these findings offer a mechanistic explanation for the impact of the brain on peripheral inflammation, define the ENS as a relay between psychological stress and gut inflammation, and suggest that stress management could serve as a valuable component of IBD care.

## INTRODUCTION

Psychological stress exerts a profound impact on inflammatory processes throughout the body,<sup>1–3</sup> suggesting that improving a patient's mental state might be a powerful yet underutilized strategy for the management of numerous diseases. The effect of psychological stress on disease severity is particularly striking in inflammatory bowel disease (IBD),<sup>4</sup> with numerous epidemiological studies supporting the hypothesis that stressful life events can exacerbate IBD flares.<sup>5–8</sup> However, the mechanistic basis for aggravated, stress-associated IBD flares is not fully understood.

In this study, we uncover several mechanisms by which psychological stress influences bowel inflammation via the enteric nervous system (ENS). Unlike the central nervous system (CNS), where responses to psychological stress have been deeply characterized,<sup>9</sup> ENS responses to stress and their consequences are less well understood. We provide insights into how the ENS may serve as a relay between brain-derived stress signals and the priming of inflammatory responses in the intestine. Our findings highlight enteric neurons and glia as possible therapeutic targets to ameliorate inflammatory sequelae of mental health impairment.

## RESULTS


### Monocytes mediate stress-driven colitis exacerbation

To investigate mechanisms underlying the impact of psychological stress on intestinal inflammation, we used a mouse model of prolonged psychological stress (restraint stress<sup>10</sup>) and induced colitis using dextran sodium sulfate (DSS) (Figure 1A). Psychological stress exacerbated intestinal inflammation, as documented by weight loss, colonoscopy, mortality, histology, and fecal lipocalin levels (Figures 1B–1E and S1A–S1C). RNA sequencing of colonic tissue revealed pronounced changes in gene expression, which were induced by psychological stress. This included downregulation of genes involved in type 2 immunity (*Il13*, *Il13ra*, and *Retnla*) as well as antimicrobial peptides (*Ang4*, *Itln1*, and *Lyz2*). In contrast, the expression of IBD-associated genes (*Duox2* and *Duoxa2*) and pro-inflammatory cytokines (*Tnf*, *Ccl2*, and *Il6*) was upregulated (Figures S1D–S1F). Restraint-stress-induced colitis exacerbation was also observed under housing conditions that ameliorate environmental stress, including thermoneutrality<sup>11</sup> and cage enrichment (Figures S1G–S1N). Although we noted slightly increased water intake in the stressed group, colitis aggravation was not caused by increased DSS consumption (Figures S1O–S1T). We also observed exacerbated colitis in stressed mice across different starting weights and durations of the stress period (Figures S1U and S1V). Interestingly, when we applied restraint stress at different time points during the experimental protocol (Figure S2A), we noted that stress experienced before the onset of colitis had the strongest effect of disease exacerbation (Figures S2B–S2E), suggesting that psychological stress may precondition the bowel for enhanced inflammation during the subsequent encounter of a colitogenic trigger. DSS-induced colitis was likewise aggravated in a model of social stress,<sup>12</sup> as demonstrated by weight loss, survival, and colonoscopy data (Figures S2F–S2I). Similarly, in an alternative IBD model<sup>13</sup> that is

based on genetic deficiency in IL-10, restraint stress led to body weight loss, elevated colonoscopy scores, higher rate of rectal prolapses, and reduced colon length (Figures S2J–S2N). In contrast, wild-type mice exposed to restraint stress did not develop macroscopic signs of colitis (Figures S2O–S2S). Together, these data from several independent mouse models suggest that psychological stress per se is not sufficient to induce overt colitis but preconditions the intestinal mucosa by inducing a pro-inflammatory state that exacerbates the consequences of a colitogenic trigger.

We next sought to identify potential effector cells of stress-exacerbated colitis. To this end, we hereafter mostly focused on the combination of restraint stress and DSS colitis due to the simplicity of these experimental paradigms. Single-cell RNA sequencing of 23,696 CD45<sup>+</sup> leukocytes isolated from colonic tissue of stressed and control mice yielded 13 distinct immune cell types, which were annotated using signatures of known lineage markers (Figures 1F, S3A, and S3B). Among all clusters, T cells, macrophages/monocytes, and innate lymphoid cells (ILCs) had the most differentially expressed genes in stressed mice (Figure S3C), nominating these cell types as potential drivers of stress-induced enhanced intestinal inflammation. We first focused on T cells, given their well-described role in the pathogenesis of colitis.<sup>14</sup> Psychological stress induced several elements of an enhanced T<sub>H</sub>17 response in the intestine (Figures S3D and S3E). However, adaptive immune cells were dispensable for stress-mediated enhancement of colitis (Figures S3F–S3I). We thus turned to ILCs, motivated by their large number of differentially regulated genes (Figure S3C), the enrichment of IL-22-producing ILCs in the intestines of stressed mice (Figures S4A and S4B), and a recent report on the role for IL-22 in stress-mediated exacerbation of enteric infection.<sup>15</sup> However, neither genetic deficiency in IL-22 nor neutralization of the IL-22-inducing cytokine IL-23 influenced the stress-mediated colitis phenotype (Figures S4C–S4I). Likewise, ILC-deficient *Rag2/Il2rg* knockout mice were as susceptible to the impact of stress on colitis as their wild-type counterparts (Figure S4J). These results suggest that neither innate nor adaptive lymphocytes are essential drivers of the intestinal inflammatory response to stress.

We therefore focused on myeloid cells, and in particular on monocytes and macrophages, given their strong transcriptional changes induced by psychological stress (Figure S3C). Sub-clustering of the single-cell data revealed five populations of myeloid cells (Figures 1F and S4K): three monocyte (Mono 1, 2, and 3) and two macrophage subsets (Mac 1 and 2). The impact of psychological stress was particularly apparent in the transcriptomes of the Mono1 and Mac2 clusters (Figure S4L). Notably, pseudotime trajectory analysis indicated an accumulation of monocytes in stressed mice (Figure 1G), which we verified by flow cytometry (Figures 1H–1K). To determine whether monocyte accumulation was functionally involved in the inflammatory phenotype, we used CCR2-DTR mice to deplete monocytes *in vivo* (Figure S4M). Indeed, depletion of CCR2<sup>+</sup> monocytes protected the mice from stress-mediated colitis aggravation (Figures 1L–1N). To dissect the molecular mechanisms by which monocytes drive inflammation under stressed conditions, we analyzed differential gene expression in myeloid cells along the pseudotime axis. We noted a strong accumulation of TNF-producing monocytes in colons



**Figure 1. Psychological stress exacerbates intestinal inflammation via colonic myeloid cells**

(A) Schematic of experimental stress-colitis paradigm.

(B–E) Colitis severity readouts.

(F) UMAP embedding of 23,696 colon leukocytes after 7 days of stress, including subclustering of myeloid cell populations.

(G) Pseudotime trajectory analysis comparing control vs. stressed myeloid cells, as well as TNF expression in Mono1 and Mac1 subclusters.

(H) Flow cytometry of CD45<sup>+</sup> Ly6G<sup>-</sup> CD11b<sup>+</sup> live colonic leukocytes. Bar charts depict relative abundances of cells in the respective quadrants (Q1–Q3).

(I–K) Absolute numbers of Ly6C<sup>+</sup> MHCII<sup>-</sup> (I), Ly6C<sup>+</sup> MHCII<sup>+</sup> (J), Ly6C<sup>-</sup> MHCII<sup>+</sup> (K) from (H).

(L–N) Colitis readouts in CCR2-DTR mice.

(O–Q) Colitis readouts in anti-TNF-treated mice.

Plotted are means  $\pm$  SEM. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$ .

See also [Figures S1–S4](#).


from stressed mice ([Figure 1G](#)), consistent with elevated transcripts of *Tnf* in colonic tissue ([Figure S1E](#)). Similar to monocyte depletion, pharmacological neutralization of TNF by treatment with a monoclonal antibody was sufficient to protect from the inflammation-enhancing effect of stress ([Figures 1O–1Q](#)). In contrast, neutralization of IL-6, another cytokine strongly induced in the context of psychological stress<sup>3</sup> ([Figures S1F and S4N](#)), was not protective ([Figures S4O–S4R](#)). Together, these experiments

suggest that psychological stress alters the landscape of intestinal myeloid cells, results in accumulation of inflammatory monocytes, and leads to TNF-mediated colitis exacerbation.

### Psychological stress impacts intestinal inflammation through glucocorticoids

We next asked how psychological stress is transmitted from the brain to the intestine. Perception of stress by the CNS results in





**Figure 2. Psychological stress impacts intestinal inflammation through glucocorticoid signaling**

(A) Serum corticosterone after 1, 7, and 14 days of stress.

(B–I) Colitis readouts in RU-486-treated (B–D) and dexamethasone-treated (E–I) stressed mice.

(J) Flow cytometry of CD45<sup>+</sup> Ly6G<sup>-</sup> CD11b<sup>+</sup> live colonic leukocytes after 7 days of dexamethasone treatment. Bar charts depict relative abundances of cells in the respective quadrants (Q1–Q3).

(K–M) Absolute abundance of cells in Q1–Q3 from (J).

(N–Q) Colitis readouts of anti-TNF treated mice receiving dexamethasone.

Plotted are means  $\pm$  SEM. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$ . Scale bar, 100  $\mu$ m.

See also Figure S5.

elevated levels of catecholamines and corticosteroids in the periphery.<sup>16</sup> Indeed, the canonical stress hormones noradrenaline and corticosterone were significantly increased in the serum of mice experiencing restraint stress (Figures 2A and S5A). To assess the impact of catecholamine release on colitis, we depleted sympathetic neurons with 6-hydroxydopamine (6-OHDA). Successful chemical sympathectomy was confirmed by strongly reduced norepinephrine concentrations (Figure S5B).

Interestingly, abrogation of adrenergic signaling seemed to further exacerbate colitis in stressed mice, as evidenced by pronounced weight loss, high mortality, and severe mucosal damage (Figures S5C–S5G). Likewise, mice treated with the  $\beta$ 2-receptor antagonist ICI-118,551 showed an exacerbated stress-induced colitis phenotype (Figures S5H–S5J). Together, these data suggest that catecholamines counteract, rather than enhance, inflammation during chronic stress.<sup>17–19</sup>

To investigate the involvement of increased glucocorticoids in stress-induced severe colitis, we pharmacologically blocked the brain-mediated induction of adrenal corticosterone release with the corticotropin-releasing hormone receptor 1 (CRHR1) antagonist antalarmin. This treatment efficiently diminished corticosterone levels (Figure S5K) and rendered the mice resistant to the impact of restraint stress on colitis (Figures S5L–S5O). Similarly, corticosterone depletion by adrenalectomy (Figures S5P–S5T) or inhibition of glucocorticoid receptor (GR) signaling using mifepristone (RU-486) prevented colitis exacerbation by psychological stress (Figures 2B–2D), suggesting that glucocorticoids mediated the detrimental effect of stress on gut inflammation. Because RU-486 is not specific to GR, but also targets the progesterone receptor, we wondered whether GR signaling was sufficient to recapitulate the effect of stress on colitis. To this end, we treated mice with the synthetic GR agonist dexamethasone, followed by exposure to DSS. Notably, dexamethasone treatment, at a concentration that matches stress-induced serum levels of corticosterone (Figures S5U and S5V), phenocopied the effects of stress and induced a severe colitis phenotype, evidenced by early mortality, severe mucosal injury as assessed by colonoscopy and histology, and reduced colon length (Figures 2E–2I). These results were surprising given that corticosteroids are used for the acute treatment of bowel inflammation.<sup>20</sup> Due to the increased receptor affinity of dexamethasone and the fact that we detected it at higher levels in intestinal tissue compared with corticosterone (Figures S5W and S5X), we also used a low-dose dexamethasone protocol, which, likewise, exacerbated colitis severity (Figures S5Y–S5AB). Dexamethasone treatment also led to monocyte accumulation as seen in stressed mice (Figures 2J–2M). Consistently, anti-TNF treatment ameliorated the chronic dexamethasone-induced sensitization to severe intestinal inflammation (Figures 2N–2Q). Together, these data indicate that chronically elevated glucocorticoids may mediate the impact of stress perception by the brain on colitis exacerbation.


### Psychological stress drives colitis exacerbation via inflammatory enteric glia

Based on these findings and recent reports that demonstrate an impact of glucocorticoids on myeloid cell migration,<sup>21</sup> we hypothesized that GR signaling in myeloid cells was responsible for the detrimental effects of psychological stress on IBD. However, mice lacking the GR gene *Nr3c1* specifically in myeloid cells (*Nr3c1*<sup>LysM</sup>) were as susceptible to the effects of stress on gut inflammation as their littermate controls, as manifested by weight loss, colonoscopy score, colon shortening, and inflammatory cytokine expression (Figures 3A–3F). This suggested that the effect of glucocorticoids on monocytes was indirect. Outside of the immune system, glucocorticoids exert a strong effect on both epithelial and neuronal cells.<sup>9,22,23</sup> Epithelial-specific GR deletion in *Nr3c1*<sup>Vil1</sup> mice did not protect mice from the aggravating effects of stress on colitis (Figures S6A–S6D). We thus tested whether cells of the ENS might be affected by chronic psychological stress. To this end, we deleted *Nr3c1* in enteric neurons and glia using *Hand2*-Cre mice. Remarkably, *Nr3c1*<sup>Hand2</sup> mice were protected from the impact of stress on colitis (Figures 3A–3F), without affecting food or water intake

(Figures S6E and S6F). Furthermore, ENS-specific deletion of *Nr3c1* also prevented the stress-induced accumulation of monocytes (Figure 3G). We observed the same protective effect of GR deficiency in the ENS when we induced colitis with an IL-10 receptor-targeting antibody (Figures S6G–S6L). Given that *Nr3c1*<sup>Hand2</sup> mice lack GR expression in both enteric neurons and glia, we sought to disentangle the individual roles of glia and neurons in the gastrointestinal tract. The large majority of adult enteric glia are characterized by *Plp1* or *Sox10* expression.<sup>24</sup> We thus generated inducible *Nr3c1*<sup>Plp1/Sox10</sup> mice and exposed them to restraint stress. Notably, deletion of GR in adult glia largely protected mice from the colitis-exacerbating effects of stress (Figures 3H–3K). Collectively, these results point to the ENS, and particularly enteric glial cells, as a critical relay between glucocorticoids derived from the hypothalamic-pituitary-adrenal axis and inflammatory reactions in the gut.

To understand the molecular effects of psychological stress on the ENS, we performed single-nucleus RNA sequencing of enteric glia and neurons using mice expressing a conditional *Sun1-GFP* allele under the control of the (non-inducible) *Sox10* promoter<sup>25</sup> (Figure S7A). We profiled 9,858 nuclei, excluded contaminating cells (epithelial, immune, and stromal cells), and identified uniform manifold approximation and projection (UMAP) clusters as neurons and glia cells based on their gene expression profile (Figures 3L and S7B). Given the protective phenotype of *Nr3c1*<sup>Plp1/Sox10</sup> mice, we first focused on glia cells. Sub-clustering analysis revealed the presence of four distinct transcriptional states, one of which was exclusively present under stressed conditions (Figures 3L and 3M). We hence termed this subset enteric glia associated with psychological stress (eGAPS). The expression profile of eGAPS was characterized by the induction of pro-inflammatory and pro-apoptotic pathways, whereas adhesion and cellular interaction pathways were downregulated (Figure S7C). Specifically, eGAPS were marked by high expression of the glucocorticoid-induced *Nur* transcription factors *Nr4a1*, *Nr4a2*, and *Nr4a3*, the ubiquitin ligase *Arih1*, the apoptosis/necroptosis mediator *Ripk1*, and the transcription factor *Stat3* (Figures 3N and S7D). Notably, chronic dexamethasone treatment was sufficient for the generation of eGAPS (Figure 3M). The transcriptional profile of dexamethasone-elicited eGAPS showed a high degree of similarity to those from stressed mice, including the *Nur* transcription factors, *Arih1*, *Ripk1*, and *Stat3* (Figure 3O). STAT3 activity was likewise increased, as evidenced by enhanced phosphorylation in enteric glia from both stressed and dexamethasone-treated mice (Figures 3P and 3Q). These data highlight the transcriptional response of enteric glia to chronic stress and nominate these cells as a possible link between glucocorticoids and intestinal inflammation.

To functionally test the role of enteric glia, we used transgenic mice enabling the inducible depletion of *Sox10*-expressing cells (*iDTR*<sup>Sox10</sup>) (Figures S7E and S7F). Remarkably, glia-depleted mice were resistant to the detrimental effect of psychological stress on intestinal inflammation (Figures 4A and 4B). The same observation was made with an alternative Cre-line that targets enteric glia via *Plp1*-Cre (*iDTR*<sup>Plp1</sup>), which conferred resistance to the colitis-exacerbating effect of dexamethasone (Figures 4C, 4D, and S7G). To avoid potential confounding



**Figure 3. The ENS relays the detrimental effect of glucocorticoids on intestinal inflammation**

(A–F) Colitis readouts (A–D) and relative gene expression levels of *Ilf1b* (E) and *Tnf* (F) in Nr3c1<sup>fl/fl</sup>, Nr3c1<sup>Hand2</sup>, and Nr3c1<sup>LyM</sup> mice.

(G) Relative abundance of Ly6C<sup>+</sup> MHCII<sup>-</sup> cells determined by flow cytometry after an adjusted experimental paradigm (only 4 days of 2% DSS).

(H–K) Colitis readouts in Nr3c1<sup>fl/fl</sup> and Nr3c1<sup>Sox10/Plp1</sup> mice.

(L) UMAP embedding of 9,858 enteric nuclei from Sox10<sup>Cre</sup>-INTACT mice after 7 days of stress with subclustering of glia cells.

(M) UMAP embedding showing the distribution of cells from control (gray), stress (red), and dexamethasone-treated (blue) mice.

(N) Ridgeline plot showing relative transcript levels of *Nr4a2* in individual glia cell clusters.

(O) Spearman correlation of the average log<sub>2</sub>FC expression of significantly regulated genes in stress compared with control and dexamethasone-treated compared with control nuclei.

(P and Q) Whole-mount IF staining for HuC/D, GFAP, and pSTAT3 (arrows indicate pSTAT3<sup>+</sup> nuclei) (P), and quantification of pSTAT3<sup>+</sup> enteric glial cell nuclei normalized to the GFAP<sup>+</sup> area (Q) after 7 days of stress or dexamethasone treatment.


Plotted are means  $\pm$  SEM. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$ . Scale bars, 10  $\mu$ m.

See also Figures S6 and S7.

effects caused by ablation of *Sox10*- or *Plp1*-expressing astrocytes, we used a pegylated variant of DT, which does not cross the blood-brain barrier and selectively ablates cells in the peripheral nervous system (*BRAINSPAReDT*).<sup>26</sup> This approach, likewise, reduced intestinal glia numbers and prevented stress-induced colitis exacerbation (Figures 4E–4G, S7H, and S7I).

Importantly, glia ablation also blocked the accumulation of colonic monocytes (Figures 4H and 4I), suggesting that communication between enteric glia and monocytes is critical for the impact of stress on colitis.

To explore possible modes of glia-myeloid cell interactions involved in the inflammatory response to stress, we generated



**Figure 4. Psychological stress drives colitis exacerbation via inflammatory enteric glia and CSF1**

(A–D) Colonoscopy readouts of stressed iDTR<sup>Sox10</sup> and iDTR<sup>fl/fl</sup> mice (A and B) and of dexamethasone-treated iDTR<sup>Plp1</sup> and iDTR<sup>fl/fl</sup> mice (C and D).

(E–G) Colitis readouts of BRAINSPAReDT-treated stressed mice.

(H and I) Flow cytometry of CD45<sup>+</sup> Ly6G<sup>-</sup> live colonic leukocytes (H) and relative abundance of CD11b<sup>+</sup> Ly6C<sup>hi</sup> cells (I) from iDTR<sup>Plp1</sup> or iDTR<sup>fl/fl</sup> mice after 7 days of stress.

(J) Circos plot showing significant cell-cell interactions determined by NicheNet.

(K) Relative expression of *Csf1* in enteric glia of control and stress mice determined by snRNA-seq.

(L) CSF1 protein concentration in the colonic muscularis layer after 7 days of stress.

(M) Percentage of colonic lymphocytes (live CD45<sup>+</sup> CD19<sup>+</sup>/CD3<sup>+</sup>/CD5<sup>+</sup>) or Ly6C<sup>hi</sup> monocytes (live CD45<sup>+</sup> Ly6G<sup>-</sup>, CD11b<sup>+</sup> Ly6C<sup>hi</sup>) expressing CSF1R as determined by flow cytometry.

(N) Relative abundance of Ly6C<sup>hi</sup> MHCII<sup>-</sup> (as a percentage of living CD45<sup>+</sup> Ly6G<sup>-</sup> CD11b<sup>+</sup>) cells in anti-CSF1 treated mice.

(O–Q) Colitis readouts of mice treated with anti-CSF1.

(R) Schematic of proposed pathway linking psychological stress to exacerbated colitis.

Plotted are means  $\pm$  SEM. \* p < 0.05, \*\* p < 0.01, \*\*\* p < 0.001, \*\*\*\* p < 0.0001.

See also [Figures S6](#) and [S7](#).

a pairwise interaction map based on our single-cell and single-nucleus transcriptome data. This analysis indicated numerous hypothetical interactions between eGAPS and myeloid cell populations in the colon ([Figure 4J](#)). We focused on interactions between eGAPS and the Mono1 cluster, given the high expression

of *Tnf* in these monocytes ([Figure 1G](#)). Among the candidate mediators of this interaction was *Csf1*, which has recently been shown to drive inflammatory myeloid cell responses in the gut.<sup>27</sup> Indeed, *Csf1* was highly expressed in enteric glial cells upon stress ([Figure 4K](#)). Furthermore, elevated CSF1 protein



could be detected in the colonic muscularis layer of stressed mice (Figure 4L). The high levels of colonic *Csf1* expression depended on GR signaling in the ENS, because *Nr3c1<sup>Hand2</sup>* mice showed blunted *Csf1* induction in response to stress (Figure S7J). Expression of the CSF1 receptor was restricted to myeloid cells (Figure S7K) and was found on the majority of Ly6C<sup>+</sup> monocytes (Figure 4M). In addition to its monocyte-recruiting function, CSF1 has been suggested to prime mononuclear phagocytes to transcribe and release TNF,<sup>28</sup> which we verified by observing a potentiating effect of CSF1 on LPS-induced TNF production by monocytes (Figures S7L and S7M). We thus hypothesized that CSF1 might mediate glia-monocyte communication and drive stress-induced aggravation of bowel inflammation. To address this, we neutralized CSF1 signaling with a monoclonal antibody. Indeed, Ly6C<sup>+</sup> MHC-II<sup>-</sup> monocyte counts were normalized upon anti-CSF1 treatment of stressed mice (Figure 4N). Intriguingly, CSF1 blockage also conferred resistance to the detrimental impact of psychological stress on colonic inflammation (Figures 4O–4Q). Collectively, these data suggest a model whereby chronic stress results in glucocorticoid exposure of enteric glia and the generation of eGAPS. Enteric glia, in turn, promote the accumulation of TNF-producing monocytes via CSF1 and enhance inflammatory responses to a colitogenic insult (Figure 4R).

### Psychological stress causes dysmotility via enteric neuron immaturity

Throughout our experiments, we consistently noticed that restraint stress, in addition to exacerbating colitis, caused a marked delay in colonic transit time (Figure 5A), in line with earlier reports.<sup>29</sup> The same phenomenon could be observed in dexamethasone-treated mice (Figure 5B). We thus examined the neuronal compartment in our single-nucleus ENS dataset, given the critical role of enteric neurons in intestinal motility<sup>30</sup> (Figures 5C and S8A–S8E). Notably, the cholinergic and nitrergic subsets of mature neurons were underrepresented in the stressed group, whereas the precursor compartment was enriched (Figure S8F). To verify this finding, we aligned the cells along a pseudotime trajectory that highlighted precursor genes, such as *Itga2*, *Nes*, *Sox2*, and *Ednrb*, and genes that drive the functions of mature neuron subsets, such as *Chat*, *Penk*, *Tac1*, and *Nos1* (Figure 5D). When we projected neurons derived from stressed and control mice onto the pseudotime trajectory, we observed that the distribution of cells was shifted toward the immature compartment under conditions of psychological stress (Figure 5E).


This finding implied that stress increased the proportion of precursor-like neurons, whereas decreasing the number of mature neurons. We validated this prediction with several orthogonal tools. First, we found higher levels of *Nes* transcript expression (Figure 5F), a larger number of Nestin-expressing neurons in whole-mount-stained myenteric plexus (Figures 5G and 5H), and elevated Nestin protein content in the muscularis of stressed mice (Figures 5I and 5J). Second, stress reduced the number of detectable nitric oxide synthase-expressing (nNOS<sup>+</sup>) neurons (Figures 5K and 5L). Third, the amount of choline acetyltransferase-expressing (ChAT<sup>+</sup>) neurons, likewise, plummeted (Figures 5K and 5M), along with reduced levels of

acetylcholine (Figure 5N). The same phenomenon could be observed in mice treated with dexamethasone, which showed a strong increase in the immature neuronal compartment (Figure 5O), lower numbers of nNOS<sup>+</sup> and ChAT<sup>+</sup> neurons (Figures 5P–5R), and reduced acetylcholine levels (Figure 5S). This lack of acetylcholine was functionally important, because restoration of nicotinic acetylcholine receptor signaling levels by exogenous supplementation of nicotine rescued the stress-induced dysmotility phenotype (Figure 5T) and ameliorated colitis after DSS exposure (Figures S8G–S8I). We did not detect a substantial amount of proliferation in enteric neurons (Figure S8J), suggesting that the stress-induced shift in neuronal composition might be caused by transcriptional changes. Together, these data reveal a surprising effect of stress on the population of enteric neurons, with a shift toward a less differentiated phenotype and reduction of nitrergic and cholinergic neurons, resulting in dysmotility.

We next explored the consequences of these stress-induced neuronal changes for DSS-induced colitis. Although total neuronal counts were not affected at steady state, DSS colitis diminished the number of neurons in stressed mice (Figure S8K). To explore the functional consequences of neuronal loss, we ablated enteric neurons in *iDTR<sup>Hand2</sup>* mice (Figure S8L), which diminished the levels of acetylcholine (Figure S8M) and massively decelerated intestinal motility (Figure S8N). These results suggest that chronic stress may render enteric neurons more susceptible to injury-induced cell death and dysmotility.

The shift from mature to precursor-like transcriptional states and DSS-induced neuronal loss were dependent on GR signaling in the ENS, because *Nr3c1<sup>Hand2</sup>* mice showed normal neuronal proportions even under conditions of restraint stress (Figures 6A–6D). We therefore hypothesized that the neuronal derangements we observed were a consequence of the eGAPS-monocyte-TNF mechanism that was triggered by glucocorticoid exposure. However, neither GR deletion in glia nor CSF1 or TNF neutralization counteracted the detrimental effect of stress on intestinal motility or ENS composition (Figures S8O–S8T). These results suggested that a different pathway of ENS-intrinsic glucocorticoid responses mediated the effect of stress on enteric neurons. To identify candidate mediators, we compared the gene expression profiles of pseudotime-high (“mature”) and pseudotime-low (“immature”) enteric neurons (Figure 6E). Interestingly, among the genes most significantly associated with the precursor state was *Tgfb2*, previously shown to be induced by dexamethasone in the eye.<sup>31</sup> Indeed, ENS cells from dexamethasone-treated mice showed a similar elevation of *Tgfb2* as neurons from stressed mice (Figure 6F). Furthermore, both transcript and protein levels of TGF-β2 were strongly induced in the colonic muscularis of stressed mice (Figures 6G and 6H). Given that TGF-β2 has previously been suggested to regulate neuronal cell death,<sup>32</sup> we asked whether TGF-β2 was a functional driver of ENS alterations in response to emotional stress. Notably, a TGF-β-neutralizing antibody prevented the shift from nNOS<sup>+</sup> to Nestin<sup>+</sup> neurons (Figures 6I–6K) and restored normal bowel motility in stressed mice (Figure 6L). This treatment also significantly, albeit incompletely, improved colitis severity (Figures 6M–6O and S8U). Monocyte counts were unaffected





**Figure 5. Psychological stress causes dysmotility via transcriptional immaturity in enteric neurons**


(A and B) Intestinal transit time after 7 days of stress (A) or dexamethasone treatment (B).  
 (C) UMAP embedding of enteric nuclei isolated from colon of control and stressed Sox10<sup>Cre</sup>-INTACT mice after 7 days of stress.  
 (D) Heatmap of differentially expressed genes across pseudotime.  
 (E) Diffusion pseudotime after 7 days of stress.  
 (F) Relative *Nestin* expression in bulk RNA sequencing of total colon after 7 days of stress.  
 (G and H) Whole-mount IF staining for HuC/D and Nestin (G) and quantification of Nestin<sup>+</sup> cells (H).  
 (I and J) Immunoblot analysis of colonic muscularis for Nestin (I) and quantification of relative Nestin protein levels (J) after 7 days of stress.  
 (K–N) Whole-mount IF staining and quantifications of HuC/D, nNOS, and ChAT (GFP) (K–L) and acetylcholine (ACh) concentrations in total colon tissue (N) after 7 days of stress.  
 (O) Relative abundance of cells with pseudotime < 0.3 after 7 days of dexamethasone treatment (determined by snRNA-seq).  
 (P–S) Whole-mount IF staining and quantifications of HuC/D, nNOS, and ChAT (GFP) (P–R) and acetylcholine (ACh) concentrations in total colon tissue (S) after 7 days of dexamethasone treatment.  
 (T) Intestinal transit time after 7 days of stress in nicotine-treated mice.  
 Plotted are means  $\pm$  SEM. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$ . Scale bars, 62  $\mu$ m (G and K) and 50  $\mu$ m (P).  
 See also Figure S8.

by TGF- $\beta$  blockade (Figure S8V), emphasizing the notion that the eGAPS-CSF1-monocyte axis was not affected by stress-mediated induction of TGF- $\beta$ 2. Taken together, glucocorticoid exposure of enteric neurons induces a precursor-like expression program that is driven by TGF- $\beta$ 2. As a result, the number of functional nitrergic and cholinergic neurons is diminished,

susceptibility to injury-induced neuronal loss is increased, and marked dysmotility develops (Figure 6P).

### Psychological stress exacerbates IBD in humans

Finally, we explored the connection of psychological stress, dysmotility, and bowel inflammation in human patients. We



**Figure 6. Enteric neuronal immaturity contributes to stress-induced dysmotility via TGF-β2**

(A–D) Whole-mount IF staining and quantification of HuC/D, nNOS, and Nestin in Nr3c1<sup>fl/fl</sup> and Nr3c1<sup>fl/fl</sup> Hand2<sup>Cre</sup> mice exposed to stress for 7 days followed by 4 days of 2% DSS in drinking water.

(E) Volcano plot of differentially expressed genes in neurons in low vs. high diffusion pseudotime.

(F) Normalized *Tgfb2* expression in the ENS nuclei of control, stress, and dexamethasone-treated mice (determined by snRNA-seq).

(G and H) Relative *Tgfb2* expression in colon determined by bulk mRNA sequencing (G) and TGF-β2 protein concentrations in colon muscularis layer (H) after 7 days of stress.

(I–K) Whole-mount IF staining and quantifications of HuC/D, nNOS, and Nestin in anti-TGF-β-treated mice after a shortened experimental paradigm (only 4 days of 2% DSS).

(L) Intestinal transit time after 7 days of stress and anti-TGF-β treatment.

(M–O) Colitis readouts of anti-TGF-β-treated mice.


(P) Schematic of the proposed mechanism linking psychological stress to enteric dysmotility.

Plotted are means ± SEM. \* p < 0.05, \*\* p < 0.01, \*\*\* p < 0.001, \*\*\*\* p < 0.0001. Scale bars, 50 μm.

See also Figure S8.

analyzed data from 502,505 individuals from the UK Biobank (Figure 7A; Table S1). Patients with ICD codes that indicate high levels of chronic psychological stress had a significantly higher risk of developing IBD during a 10-year follow-up than

participants without a stressful lifestyle (Figure 7B). In addition, psychological stress was also linked to a more severe course of IBD after diagnosis, as indicated by higher serum C-reactive protein (CRP) and increased overall mortality (Figures 7C and



**Figure 7. Psychological stress exacerbates IBD in humans**

(A) Workflow of data analysis from the UK Biobank.  
 (B) Cumulative risk (adjusted for age, sex, and BMI) for developing IBD in control vs. stressed participants.  
 (C) Serum levels of C-reactive protein in control vs. stressed IBD patients.  
 (D) Kaplan-Meier survival curve of control and stressed IBD patients with adjusted hazard ratio for age, sex, BMI.  
 (E and F) Leukocyte (E) and monocyte (F) counts in the blood of control vs. stressed participants with IBD.  
 (G) Dissatisfaction with bowel habits (scale max 10) in control vs. stressed IBD patients.  
 (H) Presence of obstipation (in %) in control vs. stressed IBD patients.  
 (I) Schematic of real-world telehealth study evaluating the effect of psychosocial stress on IBD severity.  
 (J) Spearman's correlation of questionnaire-based stress score and IBD activity score (MIAH).  
 (K) Schematic of prospective study evaluating the effect of emotional stress on IBD severity.  
 (L) Spearman's correlation of perceived stress score and colonoscopy score (0–3).  
 (M–R) Spearman's correlation of perceived stress score with expression of the indicated genes.  
 Plotted are means  $\pm$  SEM. \* p < 0.05, \*\*\*\* p < 0.0001.  
 See also [Figure S9](#) and [Table S1](#).

7D). These findings applied across the two principal types of IBD, ulcerative colitis and Crohn's disease ([Figures S9A and S9B](#)).

To investigate whether emotional stress triggered similar mechanisms as we had observed in mice, we focused on markers of

inflammation and dysmotility. Indeed, leukocyte counts, including monocytes, were elevated in stressed patients ([Figures 7E, 7F, S9C, and S9D](#)). Interestingly, stressed patients were more likely to report dissatisfaction with bowel habits and obstipation ([Figures 7G, 7H, and S9E–S9J](#)). Stressed IBD patients were also

more likely to require surgery and to develop ileus (Figures S9K and S9L). To explore whether these were general consequences of psychosocial stress or specific to IBD patients, we investigated populations in the UK Biobank that were disease-free, patients with an extraintestinal disease (rheumatoid arthritis), and patients with a different intestinal disease (irritable bowel syndrome) (Figure S9M; Table S1). We observed that dysmotility was associated with stress across all populations; however, monocyte accumulation and elevated inflammatory markers were only found in the context of intestinal disease (Figures S9N–S9AB). These observations suggest that, as in mice, psychological stress is associated with dysmotility in humans and predisposes the intestinal mucosa to a subsequent colitogenic trigger.

To substantiate these findings in a different IBD cohort, we assessed stress levels in the myIBDcoach study, a real-world, prospective, multicenter cohort study<sup>33</sup> (Figure 7I). Longitudinally assessed stress scores positively correlated with subsequent bowel inflammation as assessed by the clinically validated Monitor IBD at Home (MIAH) questionnaire<sup>34</sup> (Figure 7J), further suggesting that psychological stress may prime a heightened inflammatory response in the intestine.

To examine colonic, rather than systemic, inflammatory processes associated with stress, we embarked on a detailed prospective study of 63 IBD patients whose mental health was assessed with a questionnaire that allowed us to assign a perceived stress score to each patient. We then performed colonoscopies on these individuals and evaluated gene expression levels in biopsies obtained during the procedure (Figure 7K). Remarkably, perceived stress levels strongly correlated with colonoscopic evaluation of disease severity (Figure 7L). They also positively correlated with transcripts indicative of monocyte recruitment (Figures 7M and 7N), myeloid cell-driven inflammation (Figures 7O and 7P), and TNF production (Figure 7Q), as well as with levels of *TGFB2* (Figure 7R). Altogether, these findings provide evidence for the link between psychological stress and exacerbated intestinal inflammation in individuals with IBD.

## DISCUSSION

Chronic psychological stress is strongly associated with the severity of IBD flares,<sup>6,8,35</sup> but the underlying mechanisms remain largely unclear. In this study, we identify a cascade of cellular and molecular events that link stress perception to exacerbation of enteric inflammation, elements of which may apply to other inflammatory diseases of the gut, as well as extraintestinal disorders associated with psychological stress.

Our findings have several important implications. First, we provide important insights into the biology of enteric glial cells. Our results demonstrate that the molecular state of enteric glia and their impact on the intestinal microenvironment are influenced by CNS-derived signals. As such, enteric glia may perform previously unrecognized functions in CNS-ENS communication. Of note, the molecular profile of stress-associated astrocytes shares several features with eGAPS, including high expression levels of *Nur* family transcription factors,<sup>36,37</sup> suggesting that this stress-associated glial expression profile may emerge via common signaling mechanisms in different tissues.

Second, our study addresses a conundrum that arises from the fact that stress worsens inflammatory disease, whereas the canonical systemic mediators of psychological stress, catecholamines and glucocorticoids, are generally considered anti-inflammatory.<sup>16</sup> The induction of inflammatory enteric glia and exacerbated colitis by glucocorticoid signaling was particularly perplexing, given that the glucocorticoid receptor agonist prednisone is used to treat colitis in IBD patients. There are several possible explanations for this paradox. For instance, prolonged stress or dexamethasone treatment may induce inadequate adrenal production of corticosterone due to negative-feedback-mediated suppression of the hypothalamic-pituitary-adrenal axis.<sup>38,39</sup> However, the beneficial effects of acute GR inhibition (Figures 2B–2D) are not consistent with “adrenal suppression.” Alternatively, the balance between anti- and pro-inflammatory effects of glucocorticoids might be a temporal phenomenon.<sup>40–42</sup> Although acute glucocorticoid treatment ameliorates DSS-induced colitis,<sup>43</sup> we find that persistently elevated levels of corticosterone contribute to the appearance of eGAPS and accumulation of TNF-producing monocytes. Similarly, clinical observations have documented that only short-term steroid treatment leads to beneficial outcomes in IBD.<sup>44,45</sup>

Third, our study emphasizes the importance of considering a patient’s mental health in the clinical management of inflammatory diseases. Given that we found opposing roles of two common IBD treatment regimens (corticosteroids and monoclonal antibodies against TNF) on the severity of stress-mediated colitis in mice, it is possible that treatment effects vary depending on the psychological state of affected individuals. The evaluation of mental state, in conjunction with strategies to reduce stress, anxiety, and depression, could thus be a powerful and underutilized tool to enhance treatment success.<sup>46</sup>

## Limitations of the study

Our model implies that glia are the critical source of CSF1 and neurons the critical source of TGF- $\beta$ 2 in stress-exacerbated colitis. Although several lines of evidence support this model, the generation of new conditional knockout mice for cell-type-specific ablation of these cytokines will be required for unequivocal evidence. Additionally, our findings do not clarify the temporal sequence of events underlying TGF- $\beta$ 2-mediated neuronal alterations in response to stress. Is TGF- $\beta$ 2 induced by GR signaling and subsequently reprograms neurons to express precursor genes rather than differentiation genes? Alternatively, does GR signaling induce an immature state in neurons that is then propagated by TGF- $\beta$ 2? Similar questions regarding the induction of the eGAPS phenotype remain to be clarified.

Our model suggests that the downstream effect of glial and neuronal perturbation by psychological stress are largely distinct, with glia affecting TNF-driven inflammation and neuronal changes driving dysmotility. However, inhibition of TGF- $\beta$  signaling also provides a certain degree of protection from severe inflammation, albeit only partially. This either suggests that our dichotomous model is oversimplified, or that the rescue of motility itself helps to ameliorate bowel inflammation.

Finally, our study does not address the evolutionary purpose of exacerbated inflammatory responses to chronic stress. Systemic stress responses likely serve the function of resource



allocation during times of high energy demand. Notably, the relative benefits of a heightened inflammatory and alert state versus an immunosuppressed state that allows for reallocation of energy within the organism may depend on the source and nature of the stressful trigger.<sup>47</sup> We speculate that glucocorticoids thus serve a dual function, with acute immunosuppression purposed to centralize resources for survival of essential organs, followed by inflammatory states in the periphery in case the trigger persists. Understanding the impact of stress on intestinal inflammation in more detail may ultimately facilitate harnessing the power of brain-derived signals in the treatment of IBD.<sup>48</sup>

## STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Mice
  - UK Biobank
  - Validation cohort
  - Prospective stress cohort
- **METHOD DETAILS**
  - DSS colitis model
  - Restraint stress model
  - Experimental stress paradigm
  - Experimental paradigm with limited DSS supply
  - IL-10<sup>-/-</sup> colitis model
  - $\alpha$ IL-10R mAb colitis model
  - Social defeat stress model
  - Adrenalectomy
  - Food and water consumption measurement
  - Drug administration
  - Measurement of gastrointestinal transit times
  - Induction of glia depletion
  - Induction of enteric neuron depletion
  - Induction of CCR2<sup>+</sup> leukocyte depletion
  - Serum collection
  - Lipocalin-2 ELISA
  - Norepinephrine ELISA
  - Acetylcholine assay
  - Corticosterone ELISA
  - Dexamethasone ELISA
  - IL-6 ELISA
  - TNF ELISA
  - Western blot of colonic muscularis layer
  - Measuring of cell proliferation
  - Whole-mount intestine immunofluorescence
  - Quantification of enteric neurons
  - Colonoscopy in mice
  - Isolation of colonic leukocytes
  - Flow cytometry analysis of intestinal leukocytes
  - RNA extraction and RT-qPCR analysis

- H&E histology & pathological scoring
- Monocyte stimulation
- RNA library preparation and sequencing
- Single-Cell RNA-seq
- Single-Nucleus RNA-seq of the ENS
- NicheNet Ligand-Receptor Analysis
- ENS Diffusion Pseudotime
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
- **ADDITIONAL RESOURCES**

## SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.cell.2023.05.001>.

## ACKNOWLEDGMENTS

We acknowledge the UPenn Molecular Pathology and Imaging Core and the CDB Microscopy Core Facility, Vanda Lennon (Mayo Clinic) for ANNA-1 antibody, Ana Domingos (Oxford) for BRAINSPAReDT, Richard Flavell (Yale), Scott Durum (NIH/NCI), and Michael Abt (UPenn) for mouse lines, the Shalem lab (CHOP) for cell sorting, and the I3 Study team for sample collection. K.M.S. received a postdoctoral fellowship of the German Research Foundation (DFG, SCHN 1626/1-1), P.L. was supported by NIH F31HL160065 and 5T32AI141393-03, J.K. and S. Kircher received a Boehringer Ingelheim Fonds MD Fellowship, and N.B. and S. Kardo were supported by the German National Academic Foundation. K.B. received a research scholarship by the Evangelisches Studienwerk Villigst e.V. E.J.W. is supported by NIH grants AI155577, AI115712, AI117950, AI108545, AI082630, and CA210944 and by the Parker Institute for Cancer Immunotherapy. R.O.H. is supported by the Irma and Norman Braman Endowment, the Suzi and Scott Lustgarten Center Endowment, the Children's Hospital of Philadelphia (CHOP) Research Institute, the CHOP Center for Precision Diagnosis and Therapy for Pediatric Motility Disorders Frontier Program, NIH 1R01DK122798-01A1, 1R01DK129691-01, 1R01DK128282, and 1R21NS116574-01A1. M.L. is a Searle Scholar and Pew Biomedical Scholar and is supported by the NIH Director's New Innovator Award (DP2-AG-067511), the W.W. Smith Charitable Trust, an American Cancer Society Scholar Award, the Edward Mallinckrodt Jr Foundation, the Prevent Cancer Foundation, the Abramson Cancer Center (P30-CA-016420 Pilot), the Bassett Center, the Penn-CHOP microbiome program, the Penn Center for Research on Coronavirus and Other Emerging Pathogens, the Penn Institute for Immunology, the Penn Center for Nutritional Science and Medicine, the Penn Center for Molecular Studies in Digestive and Liver Diseases (P30-DK-050306), Penn Center for Precision Medicine (P30-DK-050306), the Penn Institute on Aging, the Penn Center of Excellence in Environmental Toxicology (P30-ES-013508), and the Borrelli Family Lynch Syndrome grant. C.A.T. is a Pew Biomedical Scholar and a Kathryn W. Davis Aging Brain Scholar, and is supported by the NIH Director's New Innovator Award (DP2AG067492), NIH 1R01DK129691-01, the Human Frontier Science Program, the Edward Mallinckrodt, Jr. Foundation, the Global Probiotics Council, the IDSA Foundation, the Thyssen Foundation, the PennCHOP Microbiome Program, the Penn Institute for Immunology, the Penn Center for Molecular Studies in Digestive and Liver Diseases (P30-DK-050306), the Penn Diabetes Research Center (P30-DK-019525), the Penn Institute on Aging, the Penn Institute for Infectious & Zoonotic Diseases, the University Research Foundation and the Dean's Innovation Fund of the University of Pennsylvania, a Borrelli Family Lynch Syndrome grant, and a Kenneth Rainin Foundation Innovator Award. The study has been approved by the UKB Access Committee (project #71300), and data were used with the permission of the NHS England and UK Biobank.

## AUTHOR CONTRIBUTIONS

K.M.S., N.B., and Y.A. conceived the study, designed and performed the experiments, interpreted the results, and wrote the manuscript. K.T., K.B., J.K.,



S. Kardo, S.P., L.D., G.T.U., S. Kircher, A.M.M., K.M.N., and M.T.J. performed experiments. P.L., L.L., M.S., K.B., H.C.D., A.R.A., and C.V.S. performed computational and statistical analyses. L.G.G., M.J.P., M.R.-C., Z.M., E.J.W., and M.B. acquired clinical data. J.D.E., E.E.F., J.H.-M., F.C.B., M.P., and R.O.H. provided essential tools and insights. M.L. and C.A.T. conceived the study, designed the experiments, interpreted the results, and wrote the manuscript.

#### DECLARATION OF INTERESTS

E.J.W. is an advisor for Danger Bio, Janssen, New Limit, Marengo, Pluto Immunotherapeutics Related Sciences, Rubius Therapeutics, Santa Ana Bio, Synthekine, and Surface Oncology. E.J.W. is a founder of and holds stock in Surface Oncology, Danger Bio, and Arsenal Biosciences.

#### INCLUSION AND DIVERSITY

We support inclusive, diverse, and equitable conduct of research. One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in their field of research or within their geographical location. One or more of the authors of this paper self-identifies as a gender minority in their field of research. One or more of the authors of this paper self-identifies as a member of the LGBTQIA+ community.

Received: July 28, 2022

Revised: April 12, 2023

Accepted: May 2, 2023

Published: May 25, 2023

#### REFERENCES

- Haykin, H., and Rolls, A. (2021). The neuroimmune response during stress: a physiological perspective. *Immunity* 54, 1933–1947. <https://doi.org/10.1016/j.immuni.2021.08.023>.
- Liu, Y.Z., Wang, Y.X., and Jiang, C.L. (2017). Inflammation: the common pathway of stress-related diseases. *Front. Hum. Neurosci.* 11, 316. <https://doi.org/10.3389/fnhum.2017.00316>.
- Qing, H., Desrouleaux, R., Israni-Winger, K., Mineur, Y.S., Fogelman, N., Zhang, C., Rashed, S., Palm, N.W., Sinha, R., Picciotto, M.R., et al. (2020). Origin and function of stress-induced IL-6 in murine models. *Cell* 182, 372–387.e14. <https://doi.org/10.1016/j.cell.2020.05.054>.
- Chang, J.T. (2020). Pathophysiology of inflammatory bowel diseases. *N. Engl. J. Med.* 383, 2652–2664. <https://doi.org/10.1056/NEJMra2002697>.
- Sgambato, D., Miranda, A., Ranaldo, R., Federico, A., and Romano, M. (2017). The role of stress in inflammatory bowel diseases. *Curr. Pharm. Des.* 23, 3997–4002. <https://doi.org/10.2174/1381612823666170228123357>.
- Sun, Y., Li, L., Xie, R., Wang, B., Jiang, K., and Cao, H. (2019). Stress triggers flare of inflammatory bowel disease in children and adults. *Front. Pediatr.* 7, 432. <https://doi.org/10.3389/fped.2019.00432>.
- Araki, M., Shinzaki, S., Yamada, T., Arimitsu, S., Komori, M., Shibukawa, N., Mukai, A., Nakajima, S., Kinoshita, K., Kitamura, S., et al. (2020). Psychologic stress and disease activity in patients with inflammatory bowel disease: a multicenter cross-sectional study. *PLoS One* 15, e0233365. <https://doi.org/10.1371/journal.pone.0233365>.
- Wintjens, D.S.J., de Jong, M.J., van der Meulen-de Jong, A.E., Romberg-Camps, M.J., Becx, M.C., Maljaars, J.P., van Bodegraven, A.A., Mahmmod, N., Markus, T., Haans, J., et al. (2019). Novel perceived stress and life events precede flares of inflammatory bowel disease: a prospective 12-month follow-up study. *J. Crohns Colitis* 13, 410–416. <https://doi.org/10.1093/ecco-jcc/jiy177>.
- McEwen, B.S., Bowles, N.P., Gray, J.D., Hill, M.N., Hunter, R.G., Karatsoreos, I.N., and Nascia, C. (2015). Mechanisms of stress in the brain. *Nat. Neurosci.* 18, 1353–1363. <https://doi.org/10.1038/nn.4086>.
- Campos, A.C., Fogaça, M.V., Aguiar, D.C., and Guimarães, F.S. (2013). Animal models of anxiety disorders and stress. *Braz. J. Psychiatry.* 35 (Suppl 2), S101–S111. <https://doi.org/10.1590/1516-4446-2013-1139>.
- Man, K., Bowman, C., Braverman, K.N., Escalante, V., Tian, Y., Bisanz, J.E., Ganeshan, K., Wang, B., Patterson, A., Bayrer, J.R., et al. (2020). A thermogenic fat-epithelium cell axis regulates intestinal disease tolerance. *Proc. Natl. Acad. Sci. USA* 117, 32029–32037. <https://doi.org/10.1073/pnas.2012003117>.
- Reber, S.O., Obermeier, F., Straub, R.H., Falk, W., and Neumann, I.D. (2006). Chronic intermittent psychosocial stress (social defeat/overcrowding) in mice increases the severity of an acute DSS-induced colitis and impairs regeneration. *Endocrinology* 147, 4968–4976. <https://doi.org/10.1210/en.2006-0347>.
- Kühn, R., Löhler, J., Rennick, D., Rajewsky, K., and Müller, W. (1993). Interleukin-10-deficient mice develop chronic enterocolitis. *Cell* 75, 263–274. [https://doi.org/10.1016/0092-8674\(93\)80068-P](https://doi.org/10.1016/0092-8674(93)80068-P).
- Maynard, C.L., and Weaver, C.T. (2009). Intestinal effector T cells in health and disease. *Immunity* 31, 389–400. <https://doi.org/10.1016/j.immuni.2009.08.012>.
- Shaler, C.R., Parco, A.A., Elhenawy, W., Dourka, J., Jury, J., Verdu, E.F., and Coombes, B.K. (2021). Psychological stress impairs IL22-driven protective gut mucosal immunity against colonising pathobionts. *Nat. Commun.* 12, 6664. <https://doi.org/10.1038/s41467-021-26992-4>.
- Russell, G., and Lightman, S. (2019). The human stress response. *Nat. Rev. Endocrinol.* 15, 525–534. <https://doi.org/10.1038/s41574-019-0228-0>.
- Schiller, M., Azulay-Deby, H., Boshnak, N., Elyahu, Y., Korin, B., Ben-Shaanan, T.L., Koren, T., Krot, M., Hakim, F., and Rolls, A. (2021). Optogenetic activation of local colonic sympathetic innervations attenuates colitis by limiting immune cell extravasation. *Immunity* 54, 1022–1036.e8. <https://doi.org/10.1016/j.immuni.2021.04.007>.
- Ağaç, D., Estrada, L.D., Maples, R., Hooper, L.V., and Farrar, J.D. (2018). The  $\beta$ 2-adrenergic receptor controls inflammation by driving rapid IL-10 secretion. *Brain Behav. Immun.* 74, 176–185. <https://doi.org/10.1016/j.bbi.2018.09.004>.
- Matheis, F., Muller, P.A., Graves, C.L., Gabanyi, I., Kerner, Z.J., Costa-Borges, D., Ahrends, T., Rosenstiel, P., and Mucida, D. (2020). Adrenergic signaling in muscularis macrophages limits infection-induced neuronal loss. *Cell* 180, 64–78.e16. <https://doi.org/10.1016/j.cell.2019.12.002>.
- Ungaro, R., Mehandru, S., Allen, P.B., Peyrin-Biroulet, L., and Colombel, J.-F. (2017). Ulcerative colitis. *Lancet* 389, 1756–1770. [https://doi.org/10.1016/S0140-6736\(16\)32126-2](https://doi.org/10.1016/S0140-6736(16)32126-2).
- Poller, W.C., Downey, J., Mooslechner, A.A., Khan, N., Li, L., Chan, C.T., McAlpine, C.S., Xu, C., Kahles, F., He, S., et al. (2022). Brain motor and fear circuits regulate leukocytes during acute stress. *Nature* 607, 578–584. <https://doi.org/10.1038/s41586-022-04890-z>.
- Madalena, K.M., and Lerch, J.K. (2017). The effect of glucocorticoid and glucocorticoid receptor interactions on brain, spinal cord, and glial cell plasticity. *Neural Plast.* 2017, 8640970. <https://doi.org/10.1155/2017/8640970>.
- Muzzi, C., Watanabe, N., Twomey, E., Meers, G.K., Reichardt, H.M., Bohnenberger, H., and Reichardt, S.D. (2021). The glucocorticoid receptor in intestinal epithelial cells alleviates colitis and associated colorectal cancer in mice. *Cell. Mol. Gastroenterol. Hepatol.* 11, 1505–1518. <https://doi.org/10.1016/j.jcmgh.2020.12.006>.
- Rao, M., Nelms, B.D., Dong, L., Salinas-Rios, V., Rutlin, M., Gershon, M.D., and Corfas, G. (2015). Enteric glia express proteolipid protein 1 and are a transcriptionally unique population of glia in the mammalian nervous system. *Glia* 63, 2040–2057. <https://doi.org/10.1002/glia.22876>.
- Mo, A., Mukamel, E.A., Davis, F.P., Luo, C., Henry, G.L., Picard, S., Urlich, M.A., Nery, J.R., Sejnowski, T.J., Lister, R., et al. (2015). Epigenomic signatures of neuronal diversity in the mammalian brain. *Neuron* 86, 1369–1384. <https://doi.org/10.1016/j.neuron.2015.05.018>.

26. Pereira, M.M.A., Mahú, I., Seixas, E., Martín-Sánchez, N., Kubasova, N., Pirzgalska, R.M., Cohen, P., Dietrich, M.O., López, M., Bernardes, G.J.L., et al. (2017). A brain-sparing diphtheria toxin for chemical genetic ablation of peripheral cell lineages. *Nat. Commun.* **8**, 14967. <https://doi.org/10.1038/ncomms14967>.
27. Grubišić, V., McClain, J.L., Fried, D.E., Grants, I., Rajasekhar, P., Csizmadia, E., Ajjola, O.A., Watson, R.E., Poole, D.P., Robson, S.C., et al. (2020). Enteric Glia Modulate Macrophage Phenotype and Visceral Sensitivity following Inflammation. *Cell Rep.* **32**, 108100. <https://doi.org/10.1016/j.celrep.2020.108100>.
28. Chapoval, A.I., Kamdar, S.J., Kremlev, S.G., and Evans, R. (1998). CSF-1 (M-CSF) differentially sensitizes mononuclear phagocyte subpopulations to endotoxin in vivo: a potential pathway that regulates the severity of gram-negative infections. *J. Leukoc. Biol.* **63**, 245–252. <https://doi.org/10.1002/jlb.63.2.245>.
29. Farhin, S., Wong, A., Delungahawatta, T., Amin, J.Y., Bienenstock, J., Buck, R., and Kunze, W.A. (2019). Restraint stress induced gut dysmotility is diminished by a milk oligosaccharide (2'-fucosyllactose) in vitro. *PLoS One* **14**, e0215151. <https://doi.org/10.1371/journal.pone.0215151>.
30. Margolis, K.G., Cryan, J.F., and Mayer, E.A. (2021). The microbiota-gut-brain axis: from motility to mood. *Gastroenterology* **160**, 1486–1501. <https://doi.org/10.1053/j.gastro.2020.10.066>.
31. Kasetti, R.B., Maddineni, P., Patel, P.D., Searby, C., Sheffield, V.C., and Zode, G.S. (2018). Transforming growth factor  $\beta 2$  (TGF $\beta 2$ ) signaling plays a key role in glucocorticoid-induced ocular hypertension. *J. Biol. Chem.* **293**, 9854–9868. <https://doi.org/10.1074/jbc.RA118.002540>.
32. Hashimoto, Y., Chiba, T., Yamada, M., Nawa, M., Kanekura, K., Suzuki, H., Terashita, K., Aiso, S., Nishimoto, I., and Matsuoka, M. (2005). Transforming growth factor beta2 is a neuronal death-inducing ligand for amyloid-beta precursor protein. *Mol. Cell. Biol.* **25**, 9304–9317. <https://doi.org/10.1128/MCB.25.21.9304-9317.2005>.
33. de Jong, M.J., van der Meulen-de Jong, A.E., Romberg-Camps, M.J., Becx, M.C., Maljaars, J.P., Cilissen, M., van Bodegraven, A.A., Mahmood, N., Markus, T., Hameeteman, W.M., et al. (2017). Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. *Lancet* **390**, 959–968. [https://doi.org/10.1016/S0140-6736\(17\)31327-2](https://doi.org/10.1016/S0140-6736(17)31327-2).
34. de Jong, M.J., Roosen, D., Degens, J.H.R.J., van den Heuvel, T.R.A., Romberg-Camps, M., Hameeteman, W., Bodelier, A.G.L., Romanko, I., Lukas, M., Winkens, B., et al. (2019). Development and validation of a patient-reported score to screen for mucosal inflammation in inflammatory bowel disease. *J. Crohns Colitis* **13**, 555–563. <https://doi.org/10.1093/ecco-jcc/ijy196>.
35. Vagianos, K., Shafer, L.A., Witges, K., Graff, L.A., Targownik, L.E., and Bernstein, C.N. (2022). Self-reported flares among people living with inflammatory bowel disease are associated with stress and worry but not associated with recent diet changes: the Manitoba living with IBD study. *JPEN J. Parenter. Enteral. Nutr.* **46**, 1686–1698. <https://doi.org/10.1002/jpen.2349>.
36. Campos-Melo, D., Galleguillos, D., Sánchez, N., Gysling, K., and Andrés, M.E. (2013). Nur transcription factors in stress and addiction. *Front. Mol. Neurosci.* **6**, 44. <https://doi.org/10.3389/fnmol.2013.00044>.
37. Saijo, K., Winner, B., Carson, C.T., Collier, J.G., Boyer, L., Rosenfeld, M.G., Gage, F.H., and Glass, C.K. (2009). A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. *Cell* **137**, 47–59. <https://doi.org/10.1016/j.cell.2009.01.038>.
38. Stein, R.B., and Hanauer, S.B. (2000). Comparative tolerability of treatments for inflammatory bowel disease. *Drug Saf.* **23**, 429–448. <https://doi.org/10.2165/00002018-200023050-00006>.
39. Pezzarossa, A., Angiolini, A., Cimicchi, M.C., D'Amato, L., Valenti, G., and Gnudi, A. (1987). Adrenal suppression after long-term exposure to occupational corticosteroids followed by rapid recovery. *Lancet* **1**, 515. [https://doi.org/10.1016/S0140-6736\(87\)92132-5](https://doi.org/10.1016/S0140-6736(87)92132-5).
40. Wilckens, T., and De Rijk, R. (1997). Glucocorticoids and immune function: unknown dimensions and new frontiers. *Immunol. Today* **18**, 418–424. [https://doi.org/10.1016/S0167-5699\(97\)01111-0](https://doi.org/10.1016/S0167-5699(97)01111-0).
41. Hong, J.Y., Lim, J., Carvalho, F., Cho, J.Y., Vaidyanathan, B., Yu, S., Annicelli, C., Ip, W.K.E., and Medzhitov, R. (2020). Long-term programming of CD8 T cell immunity by perinatal exposure to glucocorticoids. *Cell* **180**, 847–861.e15. <https://doi.org/10.1016/j.cell.2020.02.018>.
42. Cruz-Topete, D., and Cidlowski, J.A. (2015). One hormone, two actions: anti- and pro-inflammatory effects of glucocorticoids. *Neuroimmunomodulation* **22**, 20–32. <https://doi.org/10.1159/000362724>.
43. Sales-Campos, H., de Souza, P.R., Basso, P.J., Nardini, V., Silva, A., Banquieri, F., Alves, V.B.F., Chica, J.E.L., Nomizo, A., and Cardoso, C.R.B. (2017). Amelioration of experimental colitis after short-term therapy with glucocorticoid and its relationship to the induction of different regulatory markers. *Immunology* **150**, 115–126. <https://doi.org/10.1111/imm.12672>.
44. Bruscoli, S., Febo, M., Riccardi, C., and Miglioni, G. (2021). Glucocorticoid therapy in inflammatory bowel disease: mechanisms and clinical practice. *Front. Immunol.* **12**, 691480. <https://doi.org/10.3389/fimmu.2021.691480>.
45. Waljee, A.K., Wiitala, W.L., Govani, S., Stidham, R., Saini, S., Hou, J., Feagins, L.A., Khan, N., Good, C.B., Vijan, S., et al. (2016). Corticosteroid use and complications in a US inflammatory bowel disease cohort. *PLoS One* **11**, e0158017. <https://doi.org/10.1371/journal.pone.0158017>.
46. Nemirovsky, A., Ilan, K., Lerner, L., Cohen-Lavi, L., Schwartz, D., Goren, G., Sergienko, R., Greenberg, D., Slonim-Nevo, V., Sarid, O., et al. (2022). Brain-immune axis regulation is responsive to cognitive behavioral therapy and mindfulness intervention: observations from a randomized controlled trial in patients with Crohn's disease. *Brain Behav. Immun. Health* **19**, 100407. <https://doi.org/10.1016/j.bbih.2021.100407>.
47. Wang, A., Luan, H.H., and Medzhitov, R. (2019). An evolutionary perspective on immunometabolism. *Science* **363**. <https://doi.org/10.1126/science.aar3932>.
48. Koren, T., Yifa, R., Amer, M., Krot, M., Boshnak, N., Ben-Shaan, T.L., Azulay-Debby, H., Zalay, I., Avishai, E., Hajjo, H., et al. (2021). Insular cortex neurons encode and retrieve specific immune responses. *Cell* **184**, 5902–5915.e17. <https://doi.org/10.1016/j.cell.2021.10.013>.
49. Cohen, S. (1994). *Perceived Stress Scale (Mind Garden)*.
50. Bray, N.L., Pimentel, H., Melsted, P., and Pachter, L. (2016). Near-optimal probabilistic RNA-seq quantification. *Nat. Biotechnol.* **34**, 525–527. <https://doi.org/10.1038/nbt.3519>.
51. Huber, W., Carey, V.J., Gentleman, R., Anders, S., Carlson, M., Carvalho, B.S., Bravo, H.C., Davis, S., Gatto, L., Girke, T., et al. (2015). Orchestrating high-throughput genomic analysis with Bioconductor. *Nat. Methods* **12**, 115–121. <https://doi.org/10.1038/nmeth.3252>.
52. Soneson, C., Love, M.I., and Robinson, M.D. (2015). Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. *F1000Res* **4**. <https://doi.org/10.12688/f1000research.7563.1>.
53. Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: a bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140. <https://doi.org/10.1093/bioinformatics/btp616>.
54. Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., and Smyth, G.K. (2015). limma powers differential expression analyses for RNA-seq and microarray studies. *Nucleic Acids Res.* **43**, e47. <https://doi.org/10.1093/nar/gkv007>.
55. Law, C.W., Chen, Y., Shi, W., and Smyth, G.K. (2014). voom: precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biol.* **15**, R29. <https://doi.org/10.1186/gb-2014-15-2-r29>.
56. Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W.M., Hao, Y., Stoeckius, M., Smibert, P., and Satija, R. (2019). Comprehensive integration of single-cell data. *Cell* **177**, 1888–1902.e21. <https://doi.org/10.1016/j.cell.2019.05.031>.

57. Yang, S., Corbett, S.E., Koga, Y., Wang, Z., Johnson, W.E., Yajima, M., and Campbell, J.D. (2020). Decontamination of ambient RNA in single-cell RNA-seq with DecontX. *Genome Biol.* *21*, 57. <https://doi.org/10.1186/s13059-020-1950-6>.
58. Hafemeister, C., and Satija, R. (2019). Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. *Genome Biol.* *20*, 296. <https://doi.org/10.1186/s13059-019-1874-1>.
59. Linderman, G.C., Zhao, J., Roulis, M., Bielecki, P., Flavell, R.A., Nadler, B., and Kluger, Y. (2022). Zero-preserving imputation of single-cell RNA-seq data. *Nat. Commun.* *13*, 192. <https://doi.org/10.1038/s41467-021-27729-z>.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Antibodies</b>		
Anti-GFAP (dilution 1:400)	Novus Biologicals	RRID: AB_10001722
Anti-GFP (dilution 1:1000)	Aves labs	RRID: AB_2307313
Anti-NOS1 (dilution 1:400)	Millipore Sigma	RRID: AB_91824
Anti-HuCD/ANNA-1 (dilution 1:20000)	Gift from Vanda Lennon	RRID: AB_2313944
Anti-ChAT (dilution: 1:100)	Novus Biologicals	RRID: AB_1968484
Anti-Nestin (dilution: 1:200)	Santa Cruz	RRID: AB_627994
Donkey Anti-rabbit Cy2 (dilution 1:400)	Jackson Immuno Research	RRID: AB_2340612
Donkey Anti-rat Cy2, Cy5 (dilution 1:400)	Jackson Immuno Research	RRID: AB_2340673, AB_2340671
Donkey Anti-chicken Cy5 (dilution 1:400)	Jackson Immuno Research	RRID: AB_2340365
Donkey anti-goat AF647 (dilution 1:400)	Jackson Immuno Research	RRID: AB_2340436
Donkey anti-human Cy3 (dilution 1:400)	Jackson Immuno Research	RRID: AB_2340535
Rat APC/Cy7 anti-mouse CD45 (dilution 1:200)	Biolegend	RRID: AB_312981
Rat PE/Cy5 anti-mouse CD45 (dilution 1:200)	Thermo Fisher Scientific	RRID: AB_468752
Armenian Hamster PE/Cyanine5 anti-mouse TCR B (dilution 1:200)	Biolegend	RRID: AB_313432
Rat FITC anti-mouse CD64 (dilution 1:200)	Biolegend	RRID: AB_2566556
Rat PE/dazzle anti-mouse CD3 (dilution 1:200)	Biolegend	RRID: AB_2565882
Rat PE/dazzle anti-mouse CD5 (dilution 1:200)	Biolegend	RRID: AB_2819771
Rat PE/dazzle anti-mouse CD19 (dilution 1:200)	Biolegend	RRID: AB_2564000
Rat APC anti-mouse CD11c (dilution 1:200)	Biolegend	RRID: AB_313779
Rat PE/Cy7 anti-mouse CD11b (dilution 1:200)	Biolegend	RRID: AB_312799
Rat PE anti-mouse CSF1R (dilution 1:200)	Thermo Fisher Scientific	RRID: AB_2538036
Rat PerCP/Cy5.5 anti-mouse Ly6G (dilution 1:200)	Biolegend	RRID: AB_1877271
Rat BV605 anti-mouse CD103 (dilution 1:200)	Biolegend	RRID: AB_2629724
Rat BV421 anti-mouse MHCII (dilution 1:200)	Biolegend	RRID: AB_2650896
Rat BV711 anti-mouse CX3CR1 (dilution 1:200)	Biolegend	RRID: AB_2565939
Rat AF700 anti-mouse Ly6C (dilution 1:200)	Biolegend	RRID: AB_10643270
Mouse APC-eFluor 780 anti-mouse CD90 (dilution 1:200)	Thermo Fisher Scientific	RRID: AB_1272252
Rat Anti-mouse TNF $\alpha$ monoclonal antibody	BioXCell	RRID: AB_1107764
Rat Anti-mouse IL-23 (p19) monoclonal antibody	BioXCell	RRID: AB_2754551
Rat Anti-mouse CSF1 monoclonal antibody	BioXCell	RRID: AB_10950309
Mouse Anti-mouse TGF $\beta$ monoclonal antibody	BioXCell	RRID: AB_1107757
Rat anti-mouse IL-6	BioXCell	RRID: AB_1107709
Rat anti-mouse IL-10R (CD210)	BioXcell	RRID: AB_1107611
<b>Chemicals, peptides, and recombinant proteins</b>		
Dextran sulfate sodium	MP Biomedicals	160110
Tamoxifen	Sigma	T5648-1G
6-hydroxydopamine hydrochloride (6-OHDA)	Sigma	H4381-500MG
Dexamethasone	Med Chem Express	HY-14648

(Continued on next page)

**Continued**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
ICI118,551	Sigma	5052750001
RU486	Cayman Chemicals	10006317
Antalarmin	Sigma	A8727-50MG
Nicotine	Sigma	N3876
BRAINSPAReDT	Gift from Ana Domingos (Oxford)	N/A
Diphtheria Toxin	Sigma	D0564-1MG
clozapine N-oxide	Sigma	C0832
Carmine red dye	Sigma	C1022
Methylcellulose	Sigma	94378-100G
4% paraformaldehyde	Thermo scientific	J19943.K2
Methanol	Sigma	322415-1L
Donkey serum	Jackson ImmunoResearch	017-000-001
Benzyl alcohol	Sigma	305197-1L
Bezyl benzoate	Sigma	W213810-100G-K
Collagenase V	StemCell	07430, 07431, 100-0681
DTT	Sigma	10197777001
Collagenase D	Sigma	11088866001
Dispase	Sigma	D4693-1G
DNase	Roche	4716728001
TRIzol	Invitrogen	15596026
DMSO	Sigma-Aldrich	cat. # D8418
Triton X-100	Sigma-Aldrich	X100-100ML
Fetal bovine serum (FBS)	Cell center	Cat. #7210
LIVE/DEAD Fixable Aqua Cell Stain Kit	ThermoFisher	Cat. #L34957
Dulbecco's Phosphate Buffered Saline	Fisher Scientific	Cat. #11593377
LPS	Novus Biologicals	NBP2-25295
Recombinant murine CSF-1	PeptoTech	315-02
Dulbecco's Modified Eagle Medium (DMEM)	Thermo Fisher Scientific	#10569010
Penicillin-Streptomycin (10,000 U/mL)	Thermo Fisher Scientific /Gibco	#15140122

**Critical commercial assays**

Mouse Lipocalin-2 DuoSet ELISA	R&D Systems	DY1857-05
Norepinephrine ELISA Kit	IBL-America	IB89537
Amplex® Red Acetylcholine Assay Kit	Invitrogen	A12217
Corticosterone ELISA kit	DRG International	EIA-4164
IL-6 ELISA kit	R&D Systems	DY406-05
Dexamethasone ELISA kit	Elabscience	E-FS-E009
TNF ELISA kit	Thermo Fisher Scientific,	88-7324-22
Monocyte Isolation kit (BM, Mouse)	Miltenyi	130-100-629
Click-iT™ Edu Alexa Fluor™ 647 Imaging Kit	Thermo Fisher Scientific	C10340
Illumina TruSeq stranded mRNA kit	Illumina	20020594

**Deposited data**

ENS snRNASeq	GEO	GEO: GSE229322
Leukocyte ScRNASeq	GEO	GEO: GSE229321
Bulk RNASeq Colon	GEO	GEO: GSE229320

**Experimental models: Organisms/strains**

C57BL6/J	Jackson Laboratory	#000664
C57BL6/J	Charles River	027C57BL6/J

(Continued on next page)



**Continued**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
B6;CBA-Tg-Sox10-cre 1Wdr/J	Jackson Laboratory	#025807
CBA;B6-Tg(Sox10-icre/ERT2)388Wdr/J	Jackson Laboratory	#027651
B6.Cg-Tg(Plp1-cre/ERT)3Pop/J	Jackson Laboratory	#005975
C57BL/6-Gt(ROSA)26Sor <sup>tm1(HBEGF)Awai</sup> /ROSA26iDTR	Jackson Laboratory	#007900
B6;129-Gt(ROSA)26Sor <sup>tm5(CAG-Sun1/sfGFP)Nat</sup> /J	Jackson Laboratory	#021039
B6.129P2- <i>I10<sup>tm1Cgn</sup>/J</i>	Jackson Laboratory	#002251
B6.Cg-Rag2 <sup>tm1.1Cgn</sup> /J	Jackson Laboratory	#008449
B6.Cg-Tg(RP23-268L19-EGFP)2Mik/J	Jackson Laboratory	#007902
B6.Cg-Tg(Vil1-cre)1000Gum/J	Jackson Laboratory	#021504
C57BL/6NTac.Cg-Rag2 <sup>tm1Fwa</sup> Il2rg <sup>tm1Wjl</sup>	Taconic	4111-F/M
IL-17-GFP	Gift from R. Flavell (Yale)	N/A
<i>I122<sup>-/-</sup></i>	Gift from R. Flavell (Yale)	N/A
CCR2-DTR	Gift from M. Abt (UPenn)	N/A
<i>I122</i> tdTomato	Gift from S. Durum (NIH/NCI)	N/A
B6.129S6-Nr3c1 <sup>tm2.1Ljm</sup> /J	Jackson Laboratory	# 012914
B6.129P2-Lyz2 <sup>tm1(cre)Hfo</sup> /J	Jackson Laboratory	004781

**Software and algorithms**

GraphPad Prism version 8	GraphPad Software	<a href="https://www.graphpad.com">https://www.graphpad.com</a>
Fiji	ImageJ	<a href="https://imagej.net">https://imagej.net</a>
Microsoft Excel	Microsoft	<a href="https://www.microsoft.com/en-us/microsoft-365/excel">https://www.microsoft.com/en-us/microsoft-365/excel</a>
FlowJo 10	BD	<a href="http://www.flowjo.com">www.flowjo.com</a>
Statistical computing environment R	R core team	<a href="http://www.r-project.org">www.r-project.org</a>
Kallisto version 0.46	Pachter lab	<a href="https://pachterlab.github.io/kallisto/">https://pachterlab.github.io/kallisto/</a>
Seurat	Satija lab	<a href="https://satijalab.org/seurat/">https://satijalab.org/seurat/</a>
SingleR version 1.4.0	N/A	<a href="https://bioconductor.org/packages/release/bioc/html/SingleR.html">https://bioconductor.org/packages/release/bioc/html/SingleR.html</a>

**RESOURCE AVAILABILITY**

**Lead contact**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Christoph Thaiss ([thaiss@pennmedicine.upenn.edu](mailto:thaiss@pennmedicine.upenn.edu)).

**Materials availability**

Animal strains used in this study are available from The Jackson Laboratory or were provided by the indicated investigators.

**Data and code availability**

- All data and code to understand and assess the conclusions of this research are available in the main text and supplementary materials. Single-cell RNA-seq and bulk RNA-seq data have been deposited at GEO and are publicly available. Accession numbers are listed in the [key resources table](#).
- This paper does not contain original code.
- Any additional information required to reanalyze the data reported in this paper is available from the [lead contact](#) upon request.

**EXPERIMENTAL MODEL AND SUBJECT DETAILS**

**Mice**

C57BL/6J (stock no. 000664) mice were purchased from The Jackson Laboratory and allowed to acclimatize to the animal facility environment for 2 weeks before being used for experimentation. B6;CBA-Tg-Sox10-cre 1Wdr/J (025807),

CBA;B6-Tg(Sox10-icre/ERT2)388Wdr/J (027651), B6.Cg-Tg(Plp1-cre/ERT)3Pop/J (005975), C57BL/6-Gt(ROSA)26Sor<sup>tm1(HBEGF)Awai/ROSA26iDTR</sup> (007900), B6;129-Gt(ROSA)26Sor<sup>tm5(CAG-Sun1/sfGFP)Nat/J</sup> (021039), B6.129P2-*I10*<sup>tm1Cgn/J</sup>(002251), B6.Cg-*Rag2*<sup>tm1.1Cgn/J</sup> (008449), B6.Cg-Tg(Vil1-cre)1000Gum/J (021504), and B6.Cg-Tg(RP23-268L19-EGFP)2Mik/J (007902) mice were purchased from The Jackson Laboratory. C57BL/6NTac.Cg-*Rag2*<sup>tm1Fwa</sup>*I12rg*<sup>tm1Wjl</sup>(4111-F/M) were purchased from Taconic. IL-17-GFP and *I122*<sup>-/-</sup> mice were kindly provided by Richard Flavell (Yale). CCR2-DTR mice were kindly provided by Michael Abt (UPenn). *I122* tdTomato mice were kindly provided by Scott Durum (NIH/NCI). In all experiments, age- and gender-matched littermates were used. Mice were 8-12 weeks of age at the beginning of experiments. Mice were given access to a normal chow diet (Lab Diet 5010) and water *ad libitum* and maintained under a 12-hour light-dark cycle at room temperature or under thermoneutral conditions (30°C) where indicated. All mice were maintained in filter-topped cages on autoclaved food and water at the PennULAR facilities. In addition, the following enrichment items were provided where indicated: one mouse house with one opening made of cardboard, three gnawing wood pieces (4 cm in length, 1 cm in diameter). For tamoxifen-inducible Cre recombinase expression mice were injected intraperitoneally (i.p.) with 100 mg/kg body weight of tamoxifen in 200  $\mu$ l corn oil (Sigma).

All experiments were performed in accordance with the PennULAR guidelines and approved by the local IACUC. All experiments used co-housed littermates to ensure consistency of common microbiota and genetic background.

### UK Biobank

The 'UK Biobank' (UKB) is a population-based cohort study conducted in the United Kingdom from 2006 to 2010, which recruited 502,505 volunteers aged 37 to 73 years at baseline. All participants were registered with the UK National Health Service and attended an initial examination, which is followed by a long-term follow-up taking place continuously. On all analyzed visits, blood samples were taken, and physical measures were performed. All participants gave informed consent for genotyping and data linkage to medical reports. Ongoing inpatient hospital records beginning in 1996 until 2018 were used to identify diagnoses according to the International Classification of Diseases, Tenth Revision (ICD-10) codes (UKB data field 41270). The presence of the following primary ICD10 codes was evaluated: IBD was defined as the presence of K50 or K51. Ulcerative colitis was defined as K51 and Crohn's disease as K50. In a subset of IBD patients, K50 and K51 diagnoses were present. Those patients were included in both subgroups. Obstipation was defined as K59.0 and Ileus as K56. Psychological stress was defined as depression (F32, F33), or reaction to stress (F43). For comparison we used rheumatoid arthritis (M06) and irritable bowel syndrome (K58). Matching was not used since the cohorts had comparable sizes to the IBD cohort. For all ICD-10 diagnoses the date of first diagnosis was extracted. CRP (UKB data field 30710), leukocytes (UKB data field 30000), and monocytes (UKB data field 30130) at enrollment as well as a digestive health questionnaire at follow up were evaluated to assess inflammation (UKB data fields 21040, 21035, 21038). Dissatisfaction with bowel habits was scored on a scale from 0 to 10. To evaluate bowel surgery, we looked at G4 to H2 operation codes collected in UKB (data field 41272). The UK Biobank receives death notifications (age at death and primary ICD diagnosis that led to death) through linkage to national death registries. End of follow-up was defined as death or end of hospital inpatient data collection in June 2020. For IBD development after stress, stress prior to baseline examination was used and patients that experienced stress after baseline excluded to reduce confounding. The healthy control cohort only contains participants that indicated to be healthy (health rating "good" or "excellent" (UKB field 2178)). This cohort was propensity score-matched (based on age, sex and BMI to the IBD patients. All populations are described in [Table S1](#).

### Validation cohort

Clinical validation was performed in a cohort of 551 IBD patients from the Netherlands. This real-world, multicenter, prospective cohort consists of IBD patients of Maastricht University Medical Center+ and Zuyderland Medical Centre which were enrolled between June 1, 2020 and July 1, 2021 and were using myIBDcoach. MyIBDcoach is an established telemedicine platform for management of adult IBD patients. In short, myIBDcoach is a telemedicine-app which 3-monthly monitors several patient-reported outcomes (PROMs), including on disease activity, side-effects, lifestyle, nutrition and psychological factors. These periodic measurements also include the Monitor IBD at Home (MIAH) questionnaire, which is a validated PROM developed to predict endoscopic inflammation in IBD patients with good diagnostic accuracy (score 0-10, with higher scores indicating more disease activity). As for psychosocial factors, stress is measured periodically using a numeric rating scale (1-10) on which patients report their level of (perceived) stress. MyIBDcoach generates automated alerts for the back office, which is managed by nurse practitioners and IBD specialists, if certain pre-set threshold levels are exceeded. An RCT comparing myIBDcoach to standard care demonstrated that myIBDcoach is safe, has high platform adherence rates and patient satisfaction. Currently, myIBDcoach is used in over 20 Dutch hospitals, reaching over 8000 IBD patients. The current prospective myIBDcoach cohort has been approved by the Ethics Committee of Maastricht University Medical Center+ (MEC 2019-1115). In order to evaluate the association between stress and subsequent disease activity over time, a linear mixed model was constructed modelling clinical disease activity scores (measured using the MIAH questionnaire) as the dependent factor, preceding stress levels as the independent factor, and including time both as a repeated factor and as a time lag factor. In addition, a multivariable model was constructed, adjusting for disease phenotype, age at cohort entry, disease duration at cohort entry, sex, and current smoking status. Estimates of fixed effects and corresponding 95% confidence intervals (CI) were obtained. A *p* value of < 0.05 was considered statistically significant. All analyses were performed using SPSS (IBM Corp, Version 27.0).

### Prospective stress cohort

Colonoscopy was performed in a cohort of 63 prospectively recruited IBD patients. All participants filled out a standardized questionnaire (perceived stress scale<sup>49</sup>). Biopsies with sufficient mRNA yield were available for 41 individuals. The colonoscopy score was determined based on the endoscopy report (0 = no inflammatory signs, 1 = erythema, 2 = friability/erosions, 3 = ulcerations/spontaneous bleeding). The biosample collection study was approved by the University of Pennsylvania Institutional Review Board, protocol number 833338.

## METHOD DETAILS

### DSS colitis model

To induce colitis, mice were treated with 2% Dextran sulfate sodium (DSS) in drinking water for 7 days (MP Biomedicals, 160110). Mice were monitored for weight loss daily to assess disease progression. In addition, colonoscopy assessment was performed in a blinded fashion after completion of the 7 days of DSS treatment (day 7 or 8).

### Restraint stress model

To induce restraint stress, mice were placed into 50 ml polypropylene conical tubes with ventilation caps for 3 hours on 7–10 consecutive days. Stress sessions were started daily between 8–9 AM.

### Experimental stress paradigm

8–12 weeks old mice were exposed to 3 h of restraint stress for 7 days followed by 7 days of treatment with 2% DSS in drinking water. Afterwards, mice were followed up for up to 7 days, under continuation of daily restraint stress.

### Experimental paradigm with limited DSS supply

Mice were supplied with 2% DSS drinking water overnight at a dosage of 4 ml (day 1–3), 3 ml (day 4), 2 ml (day 5–6) and 1 ml (day 7) per mouse and provided with normal drinking water *ad libitum* during the light cycle to ensure equal amounts of consumed DSS between control and stress mice. Colonoscopy was performed on day 5 of DSS treatment.

### IL-10<sup>-/-</sup> colitis model

IL10<sup>-/-</sup> mice (B6.129P2-*Il10*<sup>tm1Cgn</sup>/J) were purchased from Jackson Laboratories and allowed to acclimatize to the animal facility environment for 2 weeks before being used for experimentation. IL-10<sup>-/-</sup> mice spontaneously develop a chronic IBD phenotype under specific pathogen-free conditions in our animal facility. Starting at 8–12 weeks of age, respective treatments were initiated, and mice were monitored for weight loss regularly to assess disease progression. In addition, colonoscopy assessment was performed in a blinded fashion after 30 days.

### αIL-10R mAb colitis model

To induce colitis, mice (8–12 weeks old) were treated with αIL-10R mAb (1 mg/mouse, four weekly injections, i.p., BioXcell, BE0050). One week after the fourth injection, colitis severity was assessed by the following parameters: (A) Colonoscopy (B) colon length (C) survival (D) qPCR analysis of genes of interest.

### Social defeat stress model

4–6 months old CD-1 retired breeder mice (aggressor mice) were singly housed for a minimum of 7 days with free access to food and water. To select CD-1 mice with consistent levels of aggressive behaviors, these aggressor mice were exposed to a C57BL/6J screener mice during the screening process. To this end, the screener mice were placed directly into the home cage of the aggressor for 180 s with the aggressor present. Regardless of latency to aggression, the screener mouse was kept in the cage for the full 180 s. The screening was performed 3 consecutive times. Only aggressor mice that showed consistent aggressive behavior were included in the experiments. To induce social defeat stress, experimental mice were housed in the same cage with a CD-1 aggressor separated by a divider. Every day the divider was removed for 5 minutes and experimental mice were subjected to direct exposure to the CD-1 aggressor mouse. After each cycle, experimental mice rotated into a new aggressor cage and were separated by a divider. Mice were exposed to at least 7 cycles (days) before the start of DSS treatment. Control mice underwent the same procedure but were housed with C57BL/6J mice.

### Adrenalectomy

C57BL/6J mice with surgically removed adrenal glands (ADREX) or sham controls were purchased from Charles River and allowed to acclimatize to the animal facility environment for 2 weeks before being used for experimentation. In brief, a midline incision was made, and the abdominal cavity was entered through the abdominal wall, lateral to the dorsal incision. The adrenal gland with the attached fat pad was individually pulled out of the abdominal cavity. The adrenal gland was dissected, and the fat pad returned to the abdominal cavity. The process was repeated on the opposite side. The skin incision was closed with wound clips. After surgery, the mice were supplied with 0.9% saline solution as drinking water. Success of the surgical procedure was determined by measuring corticosterone levels of randomly selected ADREX and sham mice.

### Food and water consumption measurement

Food and water consumption were measured using the BioDAQ food-intake monitoring system (Research Diets). Age- and weight-matched mice were acclimatized in the BioDAQ cages for 1 week. After acclimatization, food and water intake were measured continuously for each mouse.

### Drug administration

6-hydroxydopamine hydrochloride (6-OHDA) was diluted in 0.1% sodium-ascorbate immediately before administration and protected from light. For depletion of sympathetic neurons mice were i.p. injected with 6-OHDA at a dose of 150 mg/kg body weight followed by another injection of 100 mg/kg body weight on two consecutive days prior to the start of restraint stress. Mice were treated with an additional 100 mg/kg body weight dose after 7 days of stress treatment before initiation of DSS treatment. PBS was used for control injections.

Dexamethasone (Med Chem Express, HY-14648) solved in corn oil was administered by i.p. injection at a dose of 2.5 mg/kg body weight or at a lower dose of 2.5  $\mu$ g/kg were indicated. Mice were injected daily i.p. with IC118,551 (Sigma, I127) solved in PBS at a dose of 1.25 mg/kg body weight.

Mice were injected daily i.p. with RU486 (Cayman Chemicals, 10006317) solved in corn oil at a dose of 70 mg/kg body weight. Treatment was initiated on day 1 of DSS treatment. Antalarmin (Sigma, A8727-50MG) was administered daily via i.p. injection at a dose of 20 mg/kg body weight. Nicotine (Sigma, N3876) was administered twice a day (8 am and 8 pm) at a dose of 0.6 mg/kg body weight.

Anti-mouse TNF monoclonal antibody (BioXCell, BP0058) was injected i.p. at a dose of 25 mg/kg body weight 1 day before the start of DSS treatment and on day 3. Anti-mouse IL-23 (p19) monoclonal antibody (BioXCell, BE0313) was injected i.p. at a dose of 5 mg/kg body weight every 72h 1 day before the stress intervention and throughout the experiment. Anti-mouse CSF1 monoclonal antibody (BioXCell, BE0204) was injected i.p. at a dose of 6 mg/kg body weight every other day throughout the experiment. Anti-mouse TGF- $\beta$  was injected i.p. at a dose of 8 mg/kg body weight every other day throughout the experiment. Anti-IL-6 Ab (BioXCell, BE0046) was injected i.p. at a dose of 8 mg/kg body weight every other day throughout the experiment. PBS, corn oil or respective isotype controls were used for control injections where indicated.

### Measurement of gastrointestinal transit times

Carmine red dye (Sigma-Aldrich, C1022) was prepared as a 6% (w/v) solution in 0.5% methylcellulose (Sigma-Aldrich). Mice were gavaged with 200  $\mu$ l of the carmine solution between 09:00 am and 09:15 am local time. Animals were not fasted beforehand. Mice were separated into individual cages and monitored. Feces were collected and streaked across a sterile white napkin to assay for the presence of the red carmine dye. The time from gavage to the initial appearance of carmine in the feces was recorded as the total intestinal transit time for that animal.

### Induction of glia depletion

Mice expressing iDTR (ROSA26iDTR) were crossed to Sox10-creERT or Plp1-cre mice for specific depletion of glia cells. Mice were i.p. injected with 100 mg/kg body weight tamoxifen on two consecutive days followed by 2 i.p. injections of diphtheria toxin (DT) at a dose of 10 ng/kg body weight on 2 consecutive days. For specific depletion of peripheral glia cells mice were injected twice with *BRAINSPAReDT* at a dose of 10 ng/kg body weight on 2 consecutive days. Glia depletion was performed before initiation of stress and DSS treatment, respectively.

### Induction of enteric neuron depletion

Mice expressing iDTR (ROSA26iDTR) were crossed to Hand2-cre mice for specific depletion of enteric neurons and glia. Mice were i.p. injected with 100 mg/kg body weight tamoxifen on two consecutive days followed by 2 i.p. injections of diphtheria toxin (DT) at a dose of 10 ng/g body weight on 2 consecutive days.

### Induction of CCR2<sup>+</sup> leukocyte depletion

Mice expressing the diphtheria toxin receptor in CCR2<sup>+</sup> cells (CCR2 DTR) were i.p. injected with 10 ng/g body weight diphtheria toxin (DT) 1 day prior and every 72 h throughout the experiment.

### Serum collection

Blood was collected from the submandibular vein by cheek punch. Blood was collected in 1.1-ml z-gel micro tubes (SARSTEDT AG & Co. KG, 41.1500.005) and centrifuged at 10,000  $\times$  g for 5 min. The serum was removed and stored at -80°C until use.

### Lipocalin-2 ELISA

Lipocalin-2 concentrations in fecal samples were measured using a mouse lipocalin-2 ELISA kit (R&D Systems) according to the manufacturer's protocol. 10  $\mu$ l PBS were added per mg of stool, and a 1:1000 dilution was measured by ELISA.

### Norepinephrine ELISA

Norepinephrine concentrations were measured in serum samples and tissue lysates using a norepinephrine ELISA kit (IBL-America, IB89537) according to the manufacturer's instructions.

### Acetylcholine assay

Acetylcholine concentrations were measured using a kit (Invitrogen Amplex® Red Acetylcholine Assay Kit, A12217) according to the manufacturer's instructions.

Two centimeters of the mid colon, 4 cm distal to the ceco-colonic junction, was dissected and then homogenized in a bead tube at a concentration of 100 mg/ml in the reaction buffer. The tubes were centrifuged for 10 min at 4°C, 10,000 × g, and the supernatant was diluted 1/10 in the same buffer and measured according to the manufacturer's instructions.

### Corticosterone ELISA

Corticosterone concentrations were measured with an ultrasensitive corticosterone enzyme-linked immunosorbent assay (ELISA) kit (DRG International, EIA-4164) according to the manufacturer's instructions.

Two centimeters of the mid colon, 4 cm distal to the ceco-colonic junction, was dissected and then homogenized in a bead tube at a concentration of 100 mg/ml in the reaction buffer. The tubes were centrifuged for 10 min at 4°C, 10,000 × g, and the supernatant was diluted 1/10 in the same buffer and measured according to the manufacturer's instructions.

### Dexamethasone ELISA

Dexamethasone concentrations were measured using an enzyme-linked immunosorbent assay (ELISA) kit (Elabscience, E-FS-E009) according to the manufacturer's instructions. Whole colon was homogenized in a bead tube at a concentration of 100 mg/ml in PBS. Dexamethasone was extracted from serum or tissue lysate using ethyl-acetate and resuspended in ELISA buffer according to the manufacturer's instructions.

### IL-6 ELISA

IL-6 concentrations were measured in serum samples using an enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, DY406-05) according to the manufacturer's instructions.

### TNF ELISA

TNF concentrations were measured in cell culture supernatants using an enzyme-linked immunosorbent assay (ELISA) kit (Thermo Fisher Scientific, 88-7324-22) according to the manufacturer's instructions.

### Western blot of colonic muscularis layer

Mice were sacrificed by cervical dislocation, the colon was removed, placed in ice-cold PBS and cut open longitudinally. Luminal contents were removed by agitation and the tissue was gently stretched and pinned down in a plate coated with sylgard. The muscularis externa layer was then microscopically identified, gently incised and separated from the colon. Samples were snap frozen. Protein was isolated using RIPA buffer (sigma) containing complete mini (Roche) according to the manufacturers protocol. Protein concentrations were measured using BIO-RAD protein reagent, then adjusted to 2 µg/µl, before running on a 12% TGX FastCast Acylamide gel (Bio rad) in a Mini-Protean chamber. After running, the gel was placed in buffer to transfer the proteins to a nitrocellulose membrane with the Mini Trans-Blot cell. After blotting, the membrane was blocked in 5% non-fat dry milk diluted in TBS-tween (TBST 0.5%) for 1h to prevent unspecific antibody binding. Next, the membrane was incubated with anti-Nestin primary antibody (1:500) in 5% BSA overnight at 4°C. Subsequently, the membrane was washed thoroughly and incubated with the horseradish peroxidase (HRP)-conjugated secondary antibody at a dilution of 1:2000 in 5% dry milk. ECL substrate (Pierce, Waltham, MA, USA) was used for the development and images were acquired with an Amersham Imager 600. Protein expression was quantified with ImageJ in relation to b-actin (RRID: AB\_10950489).

### Measuring of cell proliferation

Proliferating cells in the colon of mice were visualized using the Click-iT™ EdU Alexa Fluor™ 647 Imaging Kit according to the manufacturer's instructions. Mice were exposed to restraint stress for 21 consecutive days and injected with EdU i.p. (33 mg/kg body weight) on days 8 and 9. Mice were sacrificed on day 21 and the colon was dissected and further processed for whole-mount immunofluorescence imaging.

### Whole-mount intestine immunofluorescence

In brief, mice were sacrificed by cervical dislocation, the colon was removed, and placed in ice-cold PBS. The intestine was cut open longitudinally and the luminal contents were gently washed away in PBS. The tissue was pinned down in a plate coated with Sylgard and then fixed for 30 minutes using 4% paraformaldehyde (PFA) with gentle agitation. After washing in PBS, whole-mount samples were dehydrated in 100% Methanol and permeabilized in Dent's Bleach for 1 h at room temperature with gentle shaking. Samples were then blocked for 12 h in blocking buffer (0.5% PBST + 0.02% Na<sub>3</sub>N with 5% donkey serum) at 4°C with gentle agitation. Next,



antibodies were diluted in blocking buffer at appropriate concentrations and added to tissue samples for three days at 4°C. After primary antibody incubation, the tissue was washed three times in PBS and then incubated in blocking buffer with secondary antibodies (1:400 in blocking buffer) for 24 hours at 4°C. Samples were again washed three times in PBS, dehydrated in an ascending methanol series (50%, 70%, 80%, 95%, 100%, 100%, 100%) at room temperature, then cleared with BABB (Murray's Clear) and mounted in Murray's Clear on slides. Slides were kept in the dark at 4°C until they were imaged.

Whole-mount intestine samples were imaged on an inverted LSM 710 laser scanning confocal microscope.

### Quantification of enteric neurons

Tile scans of 1 cm x 1 cm pieces of whole-mount colons were imaged at 10x magnification. Alternatively, at least 5 view fields (size 502021  $\mu\text{m}^2$ ) at 20x magnification were imaged. Images were then analyzed using ImageJ. Image brightness was adjusted, auto thresholding on single channels (Otsu) was applied and HuC/D<sup>+</sup> cells were counted automatically. Count data was then divided by the size of the surveyed area (size 502021  $\mu\text{m}^2$ ) and multiplied by 100,000 to calculate the number of counted neurons per 0.1 mm<sup>2</sup>. In case of insufficient staining quality for automatic quantification, nNOS<sup>+</sup> and ChAT<sup>+</sup> neurons as well as Nestin<sup>+</sup> cells were counted manually. All investigators were blinded during quantifications. Every data point of a given graph corresponds to a single animal. ChAT<sup>+</sup> neurons and nNOS<sup>+</sup> were normalized to the count of HuC/D<sup>+</sup> neurons.

### Colonoscopy in mice

Colonoscopy was performed using a high-resolution mouse video endoscopic system (Carl Storz, Tuttlingen, Germany). The colonoscope was advanced until the proximal colon. Macroscopic grading of colitis severity was determined based on translucency (0-3), vascularity (0-3), granularity (0-3), fibrin (0-3) and appearance of fecal content (0-3). Colonoscopy scores reflect composite scores (0-15).

### Isolation of colonic leukocytes

The intestine was flushed with cold PBS, opened longitudinally, and cut into 0.5 cm pieces. Epithelial cells and mucus were removed by incubation (45 min) with dissociation buffer at 37°C (HBSS (without Ca<sup>2+</sup> and Mg<sup>2+</sup>), 5% FBS, 2 mM EDTA, and 0.15 mg/ml (1 mM) DTT (Sigma)). After removing epithelial cells, the remaining intestinal pieces were washed thoroughly in cold PBS and then digested in HBSS containing 5% FBS, 0.6 mg/ml Collagenase V (Sigma), 1.25 mg/ml collagenase D (Sigma), 1 mg/ml Dispase II (Sigma) and 0.1 mg/ml DNase I (Roche) for 45 min at 37°C shaking at 250 rpm. The digested cell suspension was washed with PBS and passed sequentially through 100 and 40  $\mu\text{m}$  cell strainers. Lamina propria leukocytes were then used for FACS analysis or cell sorting.

### Flow cytometry analysis of intestinal leukocytes

Leukocytes were isolated from the colon (as described above). Cell viability staining was performed using the LIVE/DEAD Fixable Aqua Cell Stain Kit (ThermoFisher) according to the manufacturer's protocol. Intestinal lamina propria cells were stained with antibodies against CD45, TCRB, CD90, CD3, CD5, CD19, CD11b, CD11c, MHCII, CSF1-R, CX3CR1, Ly6C, Ly6G, CD64, CD103 (see antibody table for details). All samples were acquired by flow cytometry (FACS LSR D; BD Biosciences) and analyzed using the FlowJo software (Tree Star Inc, Ashland, OR, USA).

### RNA extraction and RT-qPCR analysis

Total RNA was extracted using TRIzol<sup>TM</sup> (Invitrogen, 15596026) according to the manufacturer's protocol and reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (4368814, Applied Biosystems). RT-qPCR was performed with the QuantiFast SYBR Green PCR Kit 2000 (204056, Qiagen) on an Applied Biosystems CFX96 machine. Expression data were normalized to *Gapdh* mRNA levels unless stated otherwise. The data are presented in arbitrary units and were calculated using the delta CT method.

### H&E histology & pathological scoring

For histology, the colon was fixed with 10% buffered formalin immediately after euthanasia and kept overnight at 4°C. After fixation, the samples were transferred into 70% ethanol before paraffin embedding. 5  $\mu\text{m}$  thick sections were cut in the sagittal plane for staining with hematoxylin and eosin (H&E). Colitis severity was evaluated based on pathological grading of H&E-stained sections by a board-certified pathologist in a blinded fashion. Composite scores are divided in 4 grades: Acute inflammation (0-3), crypt distortion (0-3), erosion (0/1), ulceration (0/1), apoptosis (0-3).

### Monocyte stimulation

Bone marrow was harvested, and red blood cells were lysed using ACK lysis buffer according to the manufacturer's instructions. Monocytes were isolated by Magnetic-activated cell sorting (MACS) using the Miltenyi Monocyte Isolation kit. Monocytes were plated in a TC treated 24 well plate (~150,000 cells per well) in D10 media (DMEM, 10% FBS, 1% Penicillin-Streptomycin) supplemented with 10 ng/ $\mu\text{l}$  of recombinant mouse CSF-1 or no CSF-1 and incubated for 16 h at 37°C. Then cells were stimulated with LPS (1  $\mu\text{g}/\text{ml}$ ) for 6 h where indicated before supernatant was collected for further analysis.

### RNA library preparation and sequencing

Libraries were prepared using the Illumina TruSeq stranded mRNA kit with Illumina TruSeq unique dual indices according to the manufacturer's instructions. Quality and quantity control of RNA and libraries were performed using an Agilent 4200 TapeStation and Qubit 4, respectively. Libraries were sequenced on an Illumina NextSeq 550 instrument to produce 75–base pair single-end reads.

Raw reads were mapped to the mouse reference transcriptome (Ensembl; *Mus musculus* version 67) using Kallisto<sup>50</sup> version 0.46. Subsequent analysis was carried out using the statistical computing environment R version 3.6.1 in RStudio and Bioconductor<sup>51</sup> version 3.8. Briefly, transcript quantification data were summarized to genes using the tximport package<sup>52</sup> and normalized using the trimmed mean of M values (TMM) method in edgeR.<sup>53</sup> Genes with <1 CPM in  $n+1$  of the samples, where  $n$  is the size of the smallest group of replicates, were filtered out. Differential Gene Expression was tested with limma-voom<sup>54,55</sup> by fitting a linear model and extracting empirical Bayes statistics.

### Single-Cell RNA-seq

For single-cell RNA sequencing paired total colon samples of control ( $n=2$ ) and stressed ( $n=2$ ) mice were collected after 7 days of restraint stress. Total colonic leukocytes were isolated as described above and brought into single-cell suspensions. Cell suspensions were stained with DAPI and sorted on a BD FACSAria Fusion sorter (BD Biosciences). Sorted cells were then immediately encapsulated into droplets and libraries prepared using the 10X Genomics platform and libraries sequenced on an Illumina NextSeq. BCL files were demultiplexed, aligned to *Mus musculus* mm10 genome, filtered, and UMI counted using Cell Ranger software v5.0 (10X Genomics), and downstream analysis performed with Seurat v4.<sup>56</sup> Data were filtered to remove cells with high mitochondrial reads (>20%), low gene detection (<200), and high gene detection (>4,000). Since certain B-cell and plasma cell genes (e.g. *Igkc* and *Jchain*) were highly expressed by lots of cells, we removed the contaminating reads using the decontX workflow.<sup>57</sup>

Normalization was performed with SCTransform<sup>58</sup> and integrated.<sup>56</sup> Subsequently, cells were clustered using Louvain clustering (resolution = 0.5), and UMAP was used for visualization (assay = "SCT", dims = 1:30). After normalization and clustering, we used ALRA (Adaptively thresholded Low-Rank Approximation)<sup>59</sup> to impute the RNA count matrix and fill in technical dropouts.

### Single-Nucleus RNA-seq of the ENS

For single-nuclei RNA sequencing paired total colon samples of control ( $n=2$ ), stress ( $n=3$ ), and dexamethasone-treated *Sun1-GFP(INTACT)<sup>Sox10</sup>* mice were collected after 7 days of restraint stress. Total colon tissue samples were rinsed, washed in cold PBS, and immediately placed on a Petri dish containing 5 ml nuclei isolation buffer (10 mM Tris pH 7.5, 25 mM KCl, 5 mM MgCl<sub>2</sub>, 250 mM sucrose, 0.1 mM DTT, 1x Complete protease Inhibitors (Roche), RNasin Plus 0.1 U/μl, 0.1% Triton) on top of a crushed ice bed. Tissue samples were chopped with a razor blade into small pieces, transferred into a 15 ml Falcon tube containing Triton, and mixed by pipetting up and down. Samples were incubated 5 min on ice with shaking every minute. After incubation 10 ml nuclei isolation buffer was added, and samples were filtered through a 40 μm cell strainer into a 15 ml Falcon tube. Samples were centrifuged for 10 min at 4°C, supernatant gently aspirated leaving about 50 μl that was resuspended with 400 μl PBS + 1% BSA. Before sorting samples were filtered through a 40 μl mesh into a FACS tube and DAPI was added before loading. Samples were sorted on a BD FACSAria Fusion sorter (BD Biosciences) (Gating see Figure S5A). Sorted nuclei were then immediately encapsulated into droplets and libraries prepared using the 10X Genomics platform and libraries sequenced on an Illumina NextSeq. BCL files were demultiplexed, aligned to mouse mm10 genome, filtered, and UMI counted using Cell Ranger software v5.0 (10X Genomics). Data was read into the Seurat single cell genomics software (v. 3.2.2) in R (v. 4.1.0). Quality control of libraries was performed to remove: (1) low-quality cells or empty droplets, (2) cell doublets or multiplets, and (3) low-quality/dying cells with extensive mitochondrial contamination. Cells expressing less than 20% mitochondrial genes with unique feature counts over 200 and less than 4000 were kept. Cell-cell normalization was performed using the LogNormalize method. Highly variable features were found using the "vst" selection method, and data was scaled to standardize the range of features, giving equal weight to each gene so highly expressed genes did not dominate analyses. This was also a preprocessing step for principal component analysis (PCA). PCA was performed on scaled data as a form of linear dimensional reduction; 50 principal components (PCs) were computed and stored. The majority of true signal (dimensionality of the dataset) was found to be captured in the first 20 PCs evidenced by an ElbowPlot. Clustering was performed on the PCA-reduced expression data at a resolution of 0.25 for the first 20 PCs. This was done using the nearest neighbor method based on Jaccard similarity. The resolution was selected based on results from analysis using the clustree package (v. 0.4.3). Resolutions tested were 0.1, 0.25, 0.3, 0.4, 0.5, 0.6, 0.75, and 0.9. Clustering for the first 20 PCs was visualized using uniform manifold approximation and projection (UMAP), a non-linear dimensionality reduction technique, which places similar cells together in a low-dimensional space. Cells were annotated manually and automatically. For automatic annotation, SingleR (v. 1.4.0), an unbiased, reference-based single-cell RNA seq annotation algorithm, was used. A reference dataset of samples with known labels is used by the algorithm to assign labels to the user's dataset based on expression profile similarities. Here, the reference dataset used was MouseRNAseqData, containing mouse bulk expression data of sorted cell populations. The dataset was obtained through the cellDex package (v. 1.0.0). SingleR returned labels for cell types within each cluster. For manual annotation, marker genes for glia (*Sox10*, *Gfra1*, *Gfap*, *Plp1*, *Gas7*), nNos<sup>+</sup> neurons (*Nos1*, *Vip*, *Etv1*), ChAT<sup>+</sup> neurons (*Chat*, *Tac1*, *Penk*, *Cas21*), and neurons (*Cas21*, *Rbfox3*, *Gap43*, *Elavl3*) were mapped onto the UMAP using the FeaturePlot() function in Seurat. Expression levels for

each cluster were visualized using the `VlnPlot()` function in Seurat. Overall unbiased, automatic annotation and manual annotation were used in conjunction to annotate clusters. The glia cluster was subsetted from the full ENS UMAP. The same procedure was followed starting with cell-cell normalization, except Seurat v. 4.0.1 was used to allow us to perform multimodal reference mapping with the dexamethasone dataset.

Glia identified from the dexamethasone dataset were defined as the 'query' object, and glia from the restraint-stress dataset was defined as the 'reference' object. Transfer anchors were determined using log normalization, PCA as the reference reduction, and the first 30 dimensions. Data were then transferred to the reference dataset, also using the first 30 dimensions. Transfer products were added as metadata to the query object, and query data was projected onto the UMAP structure of the reference object (glia from restraint stress).

### NicheNet Ligand-Receptor Analysis

Ligand-receptor analysis was performed using NicheNet (v. 1.0.0), a method that predicts which ligands in a 'sender cell' population regulate gene expression in a 'receiver' population. NicheNet was the preferred method for ligand-receptor analysis, as it predicts which ligands influence gene expression in other cells and what target genes are affected by each ligand. It does this by first prioritizing ligands based on how well a ligand can predict observed differentially expressed genes in the receiver population. It then infers active-ligand target links to see which prioritized ligands regulate which differentially expressed genes in the receiver cells. This goes beyond other models that solely predict ligand-receptor interactions where specific gene targets are not considered.

#### Analysis Pipeline

To perform NicheNet analysis, sender (eGAPS) and receiver (Mono1, Mono2, Mac1, Mac2) populations were defined. A geneset of interest was also defined, which are genes in the receiver population that may be affected by ligands in the senders. Here, the geneset of interest was defined as differentially expressed genes between stressed and control conditions in the receiver populations. Differentially expressed genes between control and stress (adjusted p-value < 0.05) were determined using Seurat (v. 3.2.2). Background genes were defined as any genes that were not differentially expressed. NicheNet network gene symbols were also converted from human to mouse. NicheNet first defined a set of potential ligands, which are ligands that are expressed by the sender cell population and bind to a putative receptor expressed by the target population. Ligand-activity analysis was then performed, which ranked the previously defined potential ligands based on their level of regulation of genes in the geneset of interest compared to the background gene set. Pearson correlation was used to determine ligand activity; calculated coefficients were between the ligand's target predictions and the observed transcriptional response. As there was overlap in terms of which cell types expressed which ligands/receptors, ligands, and receptors were assigned to their respective cell types by observing which cell types expressed the respective ligand/receptor to a degree that was higher than the average plus the standard deviation. Active ligand target links (receptors and genes targeted by top-ranked ligands) were then determined.

#### Visualization Pipeline

CircosPlot (from Circlize package v. 0.4.13) was used to display the most significant ligand-target links, links comprising the bottom 95% of lowest regulatory potential scores were removed. Each segment of ligands and targets was given a specific color and order and gaps were defined between the different segments. Links were made transparent based on ligand-target potential score; the lower the score, the more transparent the link.

### ENS Diffusion Pseudotime

Diffusion pseudotime (DPT) was performed in Python (v. 3.0), and DPT values were then loaded into Seurat (v. 3.2.2) for further analysis.

#### DPT

Control, restraint stress, and dexamethasone data (output of cellranger pipeline from 10x) were imported into Python. Data were preprocessed, filtering out (1) cells with less than 200 genes expressed and (2) genes detected in less than three cells. Cells were then again filtered, keeping cells (1) with greater than 200 genes and less than 400 genes, and (2) expressing less than 20% mitochondrial genes. Variable features were then determined, and data were normalized and scaled. Annotations (cell identities) from Seurat were added, and PCA, neighbors, and UMAP dimensionality reduction were computed. The cell with the highest expression of *Nestin* was chosen as the root cell, and pseudotime was subsequently calculated. Pseudotime values were then exported.

#### Seurat finalization

We first created a control/stressed/dexamethasone Seurat object following the pipelines outlined above. We then subsetted this object to only include mature neurons and enteric neuronal progenitor cells (ENPCs). ENPCs were defined as *Nestin* (a canonical ENPC marker) expressing cells without *Plp1* expression in order to filter out overlapping glia cells. DPT values from Python were added to the object as metadata.

### QUANTIFICATION AND STATISTICAL ANALYSIS


Data are presented as mean  $\pm$  SEM. The significance of the differences between more than two groups was evaluated using ANOVA followed by Sidak's multiple comparison test. Comparisons between two conditions were analyzed by paired or unpaired 2-tailed

student's t-test or Mann-Whitney U test dependent on normality of the data. Tests were two-sided unless a one-sided hypothesis was tested. The significance of differences in datasets consisting of repeated measurements over time (e.g., body weight development over time) were evaluated by multiple unpaired two-tailed t-tests (one per timepoint) with Holm-Sidak correction. If not indicated otherwise, asterisks in the respective figures indicate significant differences between the conditions "stress" and "stress + respective intervention". Significance of differences between two groups in survival datasets was determined by Log-rank (Mantel-cox) test. A p-value <0.05 was considered significant. In figures, asterisks denote statistical significance (\* p<0.05; \*\* p<0.01; \*\*\* p<0.001; \*\*\*\* p<0.0001), unless indicated otherwise. Experiments were repeated at least twice. Statistical analysis was performed in GraphPad Prism 8. For clinical UKB data, all continuous variables were analyzed by unpaired, two-tailed t-tests or Mann-Whitney U test, and by an appropriate multivariable model corrected for age, sex and BMI. The results are presented as mean ± SEM (normal distribution). All categorical variables were displayed as relative (%) frequencies and the corresponding contingency tables were analyzed using the Chi-square test. HRs were calculated using Cox proportional hazard regression models. Multivariable logistic regression was performed to test for independent associations. Differences were considered to be statistically significant when p<0.05. The data were analyzed using R version 4.0.2 (R Foundation for Statistical Computing; Vienna, Austria) and SPSS Statistics version 26 (IBM; Armonk, NY, USA).

### ADDITIONAL RESOURCES

The clinical trial identifier for the myIBDcoach study is NCT02173002.

# Supplemental figures



**Figure S1. Psychological stress exacerbates intestinal inflammation in different housing conditions, related to Figure 1**

(A–C) Colitis readouts after experimental stress paradigm.

(D) Bulk RNA sequencing after 7 days of stress. Heatmap of significantly differentially expressed genes.

(E and F) Relative colonic gene expression levels of *Tnf* (E) and *Il6* (F) determined by RT-qPCR (normalized to *Gapdh*).

(G–N) Colitis readouts of mice housed under thermoneutral (30°C) (G–J) and enriched (K–N) conditions. Statistical comparison in (K) is between “control + enrichment” and “stress + enrichment”.


(O and P) Food intake (O) and water consumption (P).

(Q–T) Colitis readouts after an adjusted experimental protocol with limited daily DSS supply to normalize DSS intake between groups (STAR Methods).

(U and V) Absolute body weight change of mice undergoing the standard experimental paradigm (U) or an extended experimental protocol (16 days of stress before DSS treatment).

Plotted are means +/- SEM. \* p < 0.05, \*\* p < 0.01, \*\*\* p < 0.001, \*\*\*\* p < 0.0001.





**Figure S2. Psychological stress exacerbates intestinal inflammation in several independent mouse models, related to Figure 1**


(A) Schematic representation of experimental stress-colitis model with different stress exposure periods.

(B–E) Colitis readouts.

(F–I) Colitis readouts after social stress.

(J–S) Colitis readouts of *Il10*<sup>-/-</sup> mice (J–N) and wild-type mice (O–S) exposed to restraint stress. Colonoscopy was performed after 30 days of daily stress.

Plotted are means  $\pm$  SEM. \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$ .



**Figure S3. Colonic T or B cells do not promote stress-induced inflammation, related to Figure 1**

(A) Dot plot visualization showing relative marker gene expression.

(B) UMAP embedding of 23,696 colon leukocytes after 7 days of stress.


(C) Number of DEGs in the individual UMAP clusters.

(D) Gating strategy for T<sub>H</sub>17 cells using IL-17-GFP-reporter mice.

(E) Relative abundance of T<sub>H</sub>17 cells (as % of CD45<sup>+</sup>/TCRB<sup>+</sup> cells) from ileum after 7 days of stress.

(F–I) Colitis readouts of *Rag1*<sup>-/-</sup> mice.

Plotted are means +/- SEM. \* p < 0.05, \*\*\* p < 0.001, \*\*\*\* p < 0.0001.



**Figure S4. Colonic myeloid cells promote stress-induced inflammation, related to Figure 1**

(A and B) Gating strategy (A) and relative abundance (B) of IL-22<sup>+</sup> ILC3 (as % of CD45<sup>+</sup>TCRB<sup>+</sup> cells) in ileum after 7 days of stress using IL-22-tdTomato reporter mice.

(C–F) Colitis readouts in *Il22*<sup>-/-</sup> mice.

(G) Relative gene expression (normalized to *Gapdh*) of *Il23r* after 7 days of stress.

(H and I) Colitis readouts of mice injected with anti-IL-23.

(J) Weight development of *Rag2*<sup>-/-</sup>/*Il2rg*<sup>-/-</sup> mice.


(K) Dot plot visualization showing relative marker gene expression.

(L) Number of DEGs in the individual UMAP clusters.

(M) Relative abundance of colonic Ly6C<sup>+</sup> MHCII<sup>-</sup> monocytes (as % of CD45<sup>+</sup> Ly6G<sup>-</sup> CD11b<sup>+</sup>). CCR2<sup>+</sup> cells were depleted with diphtheria toxin.


(N–R) Serum IL-6 levels (N) and colitis readouts (O–R) of anti-IL-6-treated mice.

Plotted are means +/- SEM. \* p < 0.05, \*\* p < 0.01, \*\*\*\* p < 0.0001.



**Figure S5. Canonical stress mediators modulate colitis, related to Figure 2**

(A and B) Norepinephrine levels after 3 h of stress in serum of untreated mice (A) and in spleen and colon tissue lysates of 6-OHDA and vehicle-treated mice (B). (C–J) Colitis readouts of 6-OHDA-treated mice (C–G) and ICI-118,551-treated mice (H–J). (K) Corticosterone serum levels of antalarmin-treated mice after 3 h of stress. (L–O) Colitis readouts of antalarmin-treated mice. (P–T) Serum corticosterone levels of sham and adrenalectomy mice (P), and colitis readouts (Q–T). (U–X) Levels of corticosterone in serum (U) and tissue (W), and levels of dexamethasone in serum (V) and tissue (X) of control, stressed, and dexamethasone-treated mice (for 7 days). (Y–AB) Colitis readouts after low-dose dexamethasone treatment. Plotted are means  $\pm$  SEM. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$ . Scale bar, 100  $\mu$ m.



**Figure S6. Colitis is modulated by ENS-specific glucocorticoid signaling, related to Figures 3 and 4**


(A–D) Colitis readouts of  $Nr3c1^{Vfl1}$  mice

(E and F) Food intake (E) and water consumption (F) of  $Nr3c1^{fl/fl}$  and  $Nr3c1^{Hand2}$  mice.

(G–L) Colitis readouts (G–J), and relative gene expression levels of *Il6* (K) and *Ccr2* (L) determined by RT-qPCR (normalized to *Gapdh*) of mice treated with anti-IL-10R mAb and stressed for 30 days.


Plotted are means  $\pm$  SEM. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$ .





**Figure S7. Psychological stress affects enteric glia cells, related to Figures 3 and 4**

(A) FACS of colonic nuclei isolated from Sox10-cre INTACT (Sun1-GFP) transgenic mice.  
 (B) Relative marker gene expression in UMAP embedding of snRNA-seq data of sorted Sox10 lineage-positive nuclei.  
 (C) Gene set enrichment analysis of Bioplanet pathways of the top 150 differentially up- or downregulated genes in eGAPS.  
 (D) Volcano plot of differentially expressed genes in eGAPS.  
 (E and F) Representative whole-mount staining (E) and quantification (F) of GFAP in the myenteric plexus of iDTR<sup>Sox10</sup> and iDTR<sup>fl/fl</sup> mice treated with diphtheria toxin (DT).  
 (G) Survival of dexamethasone-treated iDTR<sup>fl/fl</sup> or iDTR<sup>Plp1</sup> mice.  
 (H and I) Representative whole-mount staining (H) and quantification (I) of GFAP in the myenteric plexus of iDTR<sup>Sox10</sup> or iDTR<sup>Plp1</sup> mice treated with pegylated diphtheria toxin (BRAINSPAReDT).  
 (J) Relative gene expression level of *Csf1* determined by RT-qPCR in the colon of mice treated with anti-IL-10R for 4 weeks.  
 (K) Relative *Csf1r* mRNA expression across different UMAP clusters.  
 (L) Schematic of the isolation of monocytes and subsequent treatment in *in vitro* experiments.  
 (M) TNF levels in supernatant of monocyte cultures determined by ELISA.  
 Plotted are means +/- SEM. \* p < 0.05, \*\* p < 0.01, \*\*\* p < 0.001, \*\*\*\* p < 0.0001. Scale bars, 300  $\mu$ m (E) and 200  $\mu$ m (H).



**Figure S8. Psychological stress affects enteric neurons, related to Figures 5 and 6**

(A–E) Relative marker gene expression in UMAP embedding of snRNA-seq data of sorted Sox10 lineage-marked nuclei.

(F) Relative contributions of cells from stressed and control mice to enteric neuronal progenitor cell (ENPC), ChAT<sup>+</sup>, and nNOS<sup>+</sup> neuron clusters identified by snRNA-seq.

(G–I) Colitis readouts of nicotine-treated mice.

(J) Whole-mount IF staining for HuC/D and EdU (scale bars, 50  $\mu$ m) to measure proliferating neurons in the colon.

(K) Quantification of HuC/D<sup>+</sup> neurons in distal colon myenteric plexus of stress and control mice after 7 days of stress and after 7 days of stress followed by 4 days of 2% DSS treatment.


(L–N) Whole-mount IF staining for HuC/D and nNOS (scale bars, 62  $\mu$ m) (L), relative acetylcholine (ACh) levels in colon lysates (M), and intestinal transit time (N) of *iDTR<sup>fl/fl</sup>* and *iDTR<sup>Hand2</sup>* mice.

(O–Q) Intestinal transit time of *Nr3c1<sup>Pip1/Sox10</sup>* (O), anti-CSF1 treated (P), and anti-TNF treated mice after 7 days of stress.

(R–T) Whole-mount IF staining for HuC/D, ChAT (GFP), and nNOS (scale bars, 62  $\mu$ m) (R), relative abundance of ChAT<sup>+</sup> and nNOS neurons (T) of anti-TNF treated mice after 7 days of stress.

(U and V) Survival (U), and relative abundance of Ly6C<sup>+</sup>MHCII<sup>-</sup> monocytes (as % of CD45<sup>+</sup> Ly6G<sup>-</sup> CD11b<sup>+</sup>) (V) of stressed mice after anti-TGF- $\beta$  treatment.

Plotted are means  $\pm$  SEM. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$ . Scale bars, 50  $\mu$ m (J) and 62  $\mu$ m (L and R).



**Figure S9. Psychological stress is associated with severe IBD, related to Figure 7**

(A and B) Kaplan-Meier survival curve of control and stressed patients with ulcerative colitis (A) or Crohn's disease (B) with adjusted hazard ratio (aHR) for age, sex, and BMI.

(C–F) Blood leukocyte count (C and D), and dissatisfaction with bowel habits (E and D) in ulcerative colitis and Crohn's disease in UK Biobank participants.

(G–L) Presence of obstipation (G and H), experiencing of “current abdominal distension” (I and J) and bowel surgery or ileus in medical history (all in %) (K and L) in ulcerative colitis and Crohn's disease in UK Biobank participants.

(M) Schematic of study populations (disease-free, rheumatoid arthritis, and irritable bowel syndrome) from the UK Biobank.

(N–AB) Abdominal distension (N, S, and X), dissatisfaction with bowel habits (scale 0–10) (O, T, and Y), obstipation (P, U, and Z), blood monocytes (Q, V, and AA), and serum CRP (R, W, and AB) in disease-free individuals (N–R), individuals with rheumatoid arthritis (S–W), and individuals with irritable bowel syndrome (X–AB). Plotted are means  $\pm$  SEM. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .